Delcath Systems (DCTH) S-1 9 Apr 18 IPO registration Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	872,912
Entity Filer Category	Accelerated Filer
Trading Symbol	DCTH
Document Type	S1
Amendment Flag	false
Document Period End Date	Dec. 31, 2017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents		$ 3,999	$ 4,409
Restricted cash		1,325	27,287
Accounts receivables, net		317	403
Inventories		1,248	660
Prepaid expenses and other current assets		700	698
Deferred financing costs		0	699
Total current assets		7,589	34,156
Property, plant and equipment, net		1,298	1,083
Total assets		8,887	35,239
Current liabilities
Accounts payable		3,846	594
Accrued expenses		3,408	3,407
Convertible notes payable, net of debt discount		0	13,343
Warrant liability		560	18,751
Total current liabilities		7,814	36,095
Deferred revenue		0	30
Other non-current liabilities		395	604
Total liabilities		8,209	36,729
Commitments and contingencies
Stockholders' Equity (Deficit)
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively		0	0
Common stock, $.01 par value; 500,000,000 shares authorized; 114,055,137 and 11,805 shares issued and 114,054,851 and 11,750 shares outstanding at December 31, 2017 and December 31, 2016, respectively*	[1]	1,141	0
Additional paid-in capital		324,378	277,790
Accumulated deficit		(324,832)	(279,188)
Treasury stock, at cost; 1 share at December 31, 2017 and December 31, 2016, respectively*	[1]	(51)	(51)
Accumulated other comprehensive loss		42	(41)
Total stockholders' equity (deficit)		678	(1,490)
Total liabilities and stockholders' equity (deficit)		$ 8,887	$ 35,239
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	114,055,137	11,805
Common stock, shares outstanding (in shares)	114,054,851	11,750
Treasury stock, at cost (in shares)	1	1

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue		$ 2,715	$ 1,992	$ 1,747
Cost of goods sold		(701)	(550)	(462)
Gross profit		2,014	1,442	1,285
Operating expenses:
Selling, general and administrative expenses		9,684	9,434	10,009
Research and development expenses		10,495	8,448	6,486
Total operating expenses		20,179	17,882	16,495
Operating loss		(18,165)	(16,440)	(15,210)
Change in fair value of the warrant liability, net		15,103	12,780	564
Gain on warrant extinguishment		9,613	0	0
Loss on debt settlements and extinguishments		(29,924)	0	0
Interest expense		(21,703)	(14,328)	(67)
Other income (expense)		(41)	17	9
Net loss		(45,117)	(17,971)	(14,704)
Other comprehensive loss:
Foreign currency translation adjustments		83	(33)	(28)
Comprehensive loss		$ (45,034)	$ (18,004)	$ (14,732)
Common share data:
Basic and diluted loss per share	[1]	$ (6.50)	$ (3,707)	$ (5,096)
Weighted average number of basic and diluted shares outstanding	[1]	7,019,316	4,847	2,887
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017.

Consolidated Statements of Ope5

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016
Income Statement [Abstract]
Reverse stock split ratio	0.0029	0.0625

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	In Treasury [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (loss) income [Member]
Balance at Dec. 31, 2014	$ 18,145		$ (51)	$ 264,689	$ (246,513)	$ 20
Balance (in shares) at Dec. 31, 2014		1,740	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	349			349
Compensation expense for issuance of restricted stock	308			308
Compensation expense for issuance of restricted stock (in shares)		103
Sale of common stock, net of expenses	8,479			8,479
Sale of common stock, net of expenses (in shares)		2,109
Exercise of warrants	176			176
Exercise of warrants (in shares)		39
Fair value of warrants issued classified as liability	(4,247)			(4,247)
Fair value of warrants exercised	123			123
Net loss	(14,704)				(14,704)
Foreign currency translation	(28)					(28)
Balance at Dec. 31, 2015	8,601		$ (51)	269,877	(261,217)	(8)
Balance (in shares) at Dec. 31, 2015		3,991	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	161			161
Compensation expense for issuance of restricted stock	266			266
Compensation expense for issuance of restricted stock (in shares)		7
Sale of common stock, net of expenses	1,011			1,011
Sale of common stock, net of expenses (in shares)		1,223
Issuance of common stock and rights for payments made in shares on convertible notes payable	649			649
Issuance of common stock and rights for payments made in shares on convertible notes payable (in shares)		5,158
Fair value of beneficial conversion feature of convertible note	4,435			4,435
Exercise of warrants	1,372			1,372
Exercise of warrants (in shares)		1,426
Fair value of warrants issued classified as liability	(707)			(707)
Fair value of warrants exercised	726			726
Net loss	(17,971)				(17,971)
Foreign currency translation	(33)					(33)
Balance at Dec. 31, 2016	(1,490)		$ (51)	277,790	(279,188)	(41)
Balance (in shares) at Dec. 31, 2016		11,805	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	50			50
Compensation expense for issuance of restricted stock	79	$ 0		79
Compensation expense for issuance of restricted stock (in shares)		261
Issuance of common stock and rights for payments made in shares on convertible notes payable	40,121	$ 1,137		38,984
Issuance of common stock and rights for payments made in shares on convertible notes payable (in shares)		113,643,624
Fair value of beneficial conversion feature of convertible note	4,908			4,908
Series B preferred stock dividend	(527)				(527)
Exercise of warrants	19	$ 4		15
Exercise of warrants (in shares)		367,950
Fair value of warrants exercised	2,552			2,552
Adjustment for rounding related to Nov 2017 reverse stock split, (in shares)		31,211
Net loss	(45,117)				(45,117)
Foreign currency translation	83					83
Balance at Dec. 31, 2017	$ 678	$ 1,141	$ (51)	$ 324,378	$ (324,832)	$ 42
Balance (in shares) at Dec. 31, 2017		114,054,851	(1)

Consolidated Statements of Sto7

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016$ / shares	Dec. 31, 2017$ / shares	Dec. 31, 2016$ / shares	Dec. 31, 2015$ / shares
Statement Of Stockholders Equity [Abstract]
Common stock issued, par value		$ 0.01	$ 0.01	$ 0.01	$ 0.01
Reverse stock split ratio	0.0029	0.0625

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (45,117,000)	$ (17,971,000)	$ (14,704,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	50,000	161,000	349,000
Restricted stock compensation expense	79,000	266,000	308,000
Depreciation expense	310,000	305,000	617,000
Loss on disposal of equipment	18,000	1,000	15,000
Warrant liability fair value adjustment	(15,103,000)	(12,780,000)	(564,000)
Gain on warrant extinguishment	(9,613,000)	0	0
Non-cash interest income	(1,000)	(1,000)	(1,000)
Debt discount and deferred finance costs amortization	21,544,000	14,268,000	0
Loss on debt settlements and extinguishments	29,924,000	0	0
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	7,000	260,000	9,000
(Increase) decrease in accounts receivable	108,000	(138,000)	(52,000)
Decrease (increase) in inventories	(543,000)	95,000	(420,000)
Increase (decrease) in accounts payable and accrued expenses	3,180,000	1,507,000	(1,757,000)
Increase (decrease) in deferred revenue	(32,000)	30,000	0
Decrease in other non-current liabilities	(209,000)	(216,000)	(220,000)
Net cash used in operating activities	(15,398,000)	(14,213,000)	(16,420,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(524,000)	(258,000)	(170,000)
Increase in restricted cash	0	(1,087,000)	0
Proceeds from sales of property, plant and equipment	0	0	180,000
Net cash (used in) provided by investing activities	(524,000)	(1,345,000)	10,000
Cash flows from financing activities:
Increase in restricted cash	0	(26,200,000)	0
Net proceeds from the release of restricted cash	13,120,000	0	0
Net proceeds from sale of Series B and Series C preferred shares	2,310,000	0	0
Net proceeds from convertible note debt financing	0	31,226,000	0
Net proceeds from sale of stock and exercise of warrants	15,000	2,383,000	8,655,000
Net cash provided by financing activities	15,445,000	7,409,000	8,655,000
Fx effect on cash	67,000	(49,000)	(107,000)
Increase (decrease) in cash and cash equivalents	(410,000)	(8,198,000)	(7,862,000)
Cash and cash equivalents at beginning of period	4,409,000	12,607,000	20,469,000
Cash and cash equivalents at end of period	3,999,000	4,409,000	12,607,000
Supplemental non-cash activities:
Conversion of convertible notes	40,121,000	649,000	0
Fair value of warrants issued	16,953,000	28,472,000	4,247,000
Cashless exercise of warrants	2,537,000	0	0
Deemed dividend	527,000	0	0
Fair value of warrants exercised for cash	19,000	726,000	123,000
Series A and Series B Preferred Shares [Member]
Cash flows from financing activities:
Release of restricted cash for redemption of preferred shares	2,360,000	0	0
Cash paid to redeem preferred shares	(2,360,000)	0	0
Series C Preferred Shares [Member]
Cash flows from financing activities:
Release of restricted cash for redemption of preferred shares	590,000	0	0
Cash paid to redeem preferred shares	(590,000)	0	0
Series C Warrants [Member]
Cash flows from financing activities:
Release of restricted cash for extinguishment of Series C Warrants	7,876,000	0	0
Cash paid to extinguish of Series C Warrants	$ (7,876,000)	$ 0	$ 0

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	(1) Description of Business Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is commercially available under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT®), where it has been used at major medical centers to treat a wide range of cancers of the liver. Our primary research focus is on ocular melanoma liver metastases (mOM) and intrahepatic cholangiocarcinoma (ICC), a type of primary liver cancer, and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need. Liquidity The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has accumulated deficit of $324.8 million at December 31, 2017. As shown in the accompanying financial statements during the year ended December 31, 2017, the Company incurred net losses of $45.1 million and used $15.4 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. Adequate additional financing may not be available to us on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce or eliminate our research and development programs or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. If Delcath is not able to continue as a going concern, it is likely that holders of its common stock will lose all of their investment. The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations through May 2018. Additional working capital will be required to continue operations.

Basis of Consolidated Financial

Basis of Consolidated Financial Statement Presentation	12 Months Ended
	Dec. 31, 2017
Basis Of Condensed Consolidated Financial Statement Presentation [Abstract]
Basis of Consolidated Financial Statement Presentation	(2) Basis of Consolidated Financial Statement Presentation The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company’s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies Use of Estimates The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates. Cash Equivalents and Concentrations of Credit Risk The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution. Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying consolidated balance sheets. Accounts Receivable Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified. Inventories Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory. Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2017 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly. Property, Plant and Equipment Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with Accounting Standards Codification (ASC) 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges. Fair Value Measurements The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. • Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. • Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Revenue Recognition Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. Deferred Revenue Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied. Selling, General and Administrative Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred. Research and Development Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred. Stock Based Compensation The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expenses its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant. The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. See Note 13 for additional information. Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 are as follows: (in thousands, except share data) 2017 2016 2015 Net loss $ (45,117 ) $ (17,971 ) $ (14,704 ) Preferred stock dividends (527 ) — — Net loss, adjusted (45,644 ) (17,971 ) (14,704 ) Net loss per share – basic and diluted (6.50 ) (3,707 ) (5,096 ) Weighted average shares outstanding – basic and diluted 7,019,316 4,847 2,887 In the third quarter of 2017, the Company issued Series B Preferred Shares. A portion of the redemption price of the Series B Preferred Shares was accounted for as a deemed dividend and is discussed further in Note 10. For the years ended December 31, 2017, 2016 and 2015, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive. Shares excluded from the computation of diluted EPS: 2017 2016 2015 Stock options 127 118 135 Unvested restricted shares 283 55 103 Warrants 7,005,952 20,618 3,225 Total 7,006,362 20,791 3,463 All share numbers presented in this footnote reflect a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017 Segment Information The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments. Foreign Currency and Currency Translation Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statements of operations. The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income. Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company will adopt this standard on January 1, 2018 using the modified retrospective method. The Company has completed an analysis of its existing product sales and distribution agreement and assessed the differences in accounting for each under ASU 2014-09 compared with current revenue accounting standards. Based on that review, the Company does not expect the implementation of ASU 2014-09 to have a material quantitative impact on its consolidated financial statements as the timing of revenue recognition for product sales is not expected to change considerably. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company has adopted this guidance. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company will adopt this standard on January 1, 2018 and does not anticipate that this guidance will materially impact its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventories	(4) Inventories Inventories consist of: (in thousands) December 31, 2017 December 31, 2016 Raw materials $ 298 $ 346 Work-in-process 721 214 Finished goods 229 100 Total Inventory $ 1,248 $ 660

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2017
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses And Other Current Assets	(5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include the following: (in thousands) December 31, 2017 December 31, 2016 Insurance premiums $ 421 $ 501 Financing costs 70 — Security deposit 50 50 Other 1 159 147 Total prepaid expenses and other current assets $ 700 $ 698 1

Property, Plant, and Equipment

Property, Plant, and Equipment	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property, Plant, and Equipment	(6) Property, Plant, and Equipment Property, plant, and equipment consists of: (in thousands) December 31, 2017 December 31, 2016 Buildings and land $ 579 $ 556 Enterprise hardware and software 1,744 1,532 Leaseholds 1,705 1,504 Equipment 971 940 Furniture 175 354 Property, plant and equipment, gross 5,174 4,886 Accumulated depreciation (3,876 ) (3,803 ) Property, plant and equipment, net $ 1,298 $ 1,083 Depreciation expense for the years ended December 31, 2017, 2016 and 2015 was $0.3 million, $0.3 million, $0.6 million, respectively.

Current Accrued Expenses

Current Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Current Accrued Expenses	(7) Current Accrued Expenses Current accrued expenses include the following: (in thousands) December 31, 2017 December 31, 2016 Clinical trial expenses $ 869 $ 1,365 Compensation, excluding taxes 1,124 933 Professional fees 221 286 Short-term portion of lease restructuring 209 216 Other 1 985 607 Total accrued expenses $ 3,408 $ 3,407 1

Restructuring Expenses

Restructuring Expenses	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Restructuring Expenses	(8) Restructuring Expenses In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of December 31, 2017, the total remaining lease restructuring liability for its leased office space was approximately $0.6 million, of which approximately $0.2 million and $0.4 million were included in Accrued expenses and Other non-current liabilities on the consolidated balance sheets, respectively. The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2017: (in thousands) Lease Liability Reserve balance at December 31, 2016 $ 820 Charges — Payments/Utilizations (216 ) Reserve balance at December 31, 2017 $ 604

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Convertible Notes Payable	(9) Convertible Notes Payable As of December 31, 2017, the senior secured convertible notes (the “Notes”) had been repaid in full and were no longer outstanding. On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of Notes and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. The balance was released throughout 2017. In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire approximately 20,000 shares of Common Stock. The provisions in the Series C Warrants required the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants. On April 2, 2017 the Company entered into separate warrant repurchase agreements (the “Warrant Repurchase Agreements”) with each of the investors named on the Schedule of Buyers attached to the SPA. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case were paid to the respective investor, in exchange for cancellation of the Warrants issued to each investor under the SPA. As a result of the extinguishment, the Company recognized a gain of $9.6 million, representing the difference between the fair value of the liability as of the extinguishment date of $17.5 million related to the Series C Warrants and the $7.9 million in cash returned to the Note holders to extinguish the liability. The Company had agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions were met, the installment payment was, at the election of the Company, automatically converted into shares of Common Stock at a conversion rate defined in the SPA. At any time after the issuance of the Notes, the Notes were convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $1,536.50, subject to adjustment as provided in the Notes. As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants 35.0 . All debt issuance costs were accounted for as a deferred asset and were amortized over the life of the Notes. As of December 31, 2017, the Company had incurred approximately $2.2 million in debt issuance costs all of which were amortized or expensed as of December 31, 2017. Restructuring Agreement On August 28, 2017, the Company entered into a Restructuring Agreement (the “Agreement”) with one of the institutional investors (the “Investor”) who was a party to the SPA. As of the date the Agreement was entered into, the Investor held $11,444,637 aggregate principal amount of Notes of which there was $10,092,857 aggregate Restricted Principal, (as defined in the Notes) of Notes (the “Restricted Notes”), secured by such aggregate cash amount held in a collateral account of the Company in the same amount (the “Restricted Cash”) and (y) $1,351,780 principal of Notes (the “Unrestricted Notes”), (ii) 4,200 shares of Series A Preferred Stock and (iii) 2,006 shares of Series B Convertible Preferred Stock. Pursuant to the Agreement, (a) on the date thereof the Company and the Investor took the following actions (the “Initial Restructuring”): (i) the Investor released restrictions on $1,650,000 of Restricted Cash (the “Initial Release”), (ii) the Investor consented to the use of additional Restricted Cash to effect redemptions of the Series A Preferred Shares and the Series B Preferred Shares, (iii) the Investor cancelled $1,200,000 aggregate principal of the Notes (such portion of the Notes, the “Cancellation Note”), (iv) the Company redeemed all the Series A Preferred Shares outstanding for a cash payment to the Investor of $4.20 and (v) the Company redeemed the Series B Preferred Shares for a cash payment to the Investor of $2,006,000 and (b) upon the consummation of a reverse stock split of our Common Stock of at least twenty to one (the “Reverse Stock Split Event”, and such date, the “Reverse Stock Split Date”) by September 15, 2017, the Company and the Investor shall have taken the following actions (the “Additional Restructuring”, and together with the Initial Restructuring, the “Restructuring”): (i) the Investor shall consent to the use of Restricted Cash to effect redemptions of $4,000,000 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Redemption Notes”), (ii) the Company shall redeem the Redemption Notes for a redemption price of $6,436,852.80 (the “Redemption Price”) and (iii) the Company shall exchange (the “Exchange”), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, $2,436,852.80 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Exchange Notes”, and together with the Redemption Notes, the “Restructured Notes”) for new warrants to purchase 114,286 shares of its Common Stock (the “New Warrants”, as exercised, the “New Warrant Shares”). The New Warrants expire on the 42 month anniversary of the date of issuance and bear an exercise price of $122.50 per share (which shall be adjusted to the new lower purchase price per share if there is a subsequent “down round” financing). The Investor, in lieu of an exercise of the New Warrants pursuant to a cash payment of the aggregate exercise price of the number of New Warrants being exercised, may exercise the New Warrants, in whole or in part, by electing instead to receive upon such exercise two shares and one hundred and twenty-five thousandths of a share of the Company’s Common Stock for each Warrant Share exercised pursuant to this provision. The transactions set forth herein were being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 144(d)(3)(ii) of the 1933 Act. As a result of not having effected a reverse stock split by September 15, 2017, the Additional Restructuring did not occur. This transaction was accounted for as a debt settlement that resulted in extinguishment. As such, the $1.9 million difference between the fair value of the common shares issued and the $1.2 million debt settlement was recorded as a loss on debt settlement. Amendment to Restructuring Agreement As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,551 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75 th November 2017 Exchange Agreement On November 15, 2017, the Company entered into exchange agreements (“Exchange Agreement”) with each of the two investors from its June 2016 private placement of senior secured convertible notes as contemplated by the SPA. As of November 15, 2017, those investors held $11,157,970 aggregate principal amount of Notes. On November 15, 2017, the Company authorized a new series of senior secured convertible notes of the Company, in the aggregate original principal amount as set forth above (the “Exchange Notes”), which Exchange Notes convertible into shares of Common Stock in accordance with the terms of the Exchange Notes. Subject to the terms and conditions of the Exchange Agreements, the Company and the investors exchanged for (a) $10,562,425 aggregate principal amount of the Exchange Notes (the “New Notes”, and the shares of Common Stock issuable pursuant to the terms of the New Notes, including, without limitation, upon conversion or otherwise, collectively, the “New Conversion Shares”) and (b) warrants to purchase an aggregate of 7,000,000 shares of Common Stock at an initial exercise price of $2.45. The warrants have a five year term. The New Notes had the following terms: • The initial conversion price was $1.50 per share for an optional conversion and at any time, an investor could have instead engaged in an alternate conversion for which the conversion price was 82% (75% if an event of default) of the lowest vwap for the Company’s common stock on the three trading days prior to and including the date of the conversion. • The obligation to prepay the New Notes was extended to March 31, 2018, except in the case of an event of default or change in control. • Assuming equity conditions as stated in the New Notes are met, the investors consented to release cash to the Company from the existing controlled accounts upon conversion of the New Notes. The November Exchange Agreement was accounted for as an extinguishment. As such, the New Notes were recorded at their calculated fair value of $15.2 million, the related November 2017 Warrants were recorded as a derivative liability at their calculated fair value of $14.4 million and the difference between the fair value of the New Notes, the fair value of the warrants issued, and the carrying amount of the old notes was recorded as a $19.0 million loss on extinguishment. As with the Notes issued in June 2016, the New Notes also contained a beneficial conversation feature. The value of this feature was considered in the fair value calculations of the New Notes and was determined to be $4.9 million of the $15.2 million total fair value. The $10.3 million fair value of the New Notes was accreted up to the face value of $10.6 million over the term of the New Notes with the $0.3 million difference charged to interest expense. The $4.9 million beneficial conversion feature was fully credited to Additional paid-in capital as the New Notes were fully satisfied under the December 28, 2017 Exchange Agreement. The November 2017 Warrants that were issued in connection with the November Exchange Agreement assessed at the end of each reporting period with any changes in fair value being recognized as derivative income or expense. December 28, 2017 Exchange Agreements On December 28, 2017, the Company entered into exchange agreements (“Exchange Agreements”), with each of the two investors from its June 2016 private placement of senior secured convertible notes (as further exchanged, the “Notes”) originally issued pursuant the SPA. Pursuant to the Exchange Agreements, the Company (i) extinguished its remaining $3,027,408 in outstanding obligations under the New Notes in full, (ii) obtained a release of restrictions on $2,046,898 in restricted cash held in its control accounts, (iii) issued to the investors 14.8 million shares (the “Shares”) of its common stock and rights (“Rights”) to receive 108.9 million shares of common stock to the extent such issuance of Shares would otherwise result in the beneficial ownership by any such investor of more than 4.9% or 9.9% of its issued and outstanding stock), as applicable, for an aggregate of 123,708,735 shares of its common stock (in each case, subject to trading restrictions set forth in leak out agreements the Company separately entered into with each) and (iv) a cash payment to the investors of $829,831 from the restricted cash held in the control accounts. The 14.8 million shares were issued and outstanding at December 31, 2017. The rights were fully exercised in January 2018. This transaction resulted in the settlement of $3.0 million in debt. The $3.7 million difference between the fair value of the shares and rights issued for shares and the carrying value of the Notes was recorded as a loss on debt settlement. The Company has issued shares of Common Stock and Preferred Stock as payments of principal (including certain early repayments at the option of the holders) and effected a retirement under the Notes and New Notes as follows: Number of Shares of Common Stock Number of Shares of Preferred Stock Applicable Conversion Price Reduction in Principal January 12, 2017 11,753 — $ 126.00 $ 1,478,318 January 26 - February 1, 2017 1 4,857 — $ 112.00 $ 544,000 February 10, 2017 43,882 — $ 70.00 $ 3,045,817 February 23 - March 2, 2017 1 2,571 — $ 49.00 $ 125,999 March 13, 2017 117,297 — $ 38.50 $ 4,417,829 April 10, 2017 169,061 — $ 21.00 $ 3,621,286 May 9, 2017 109,367 — $ 17.50 $ 1,913,915 June 7 / July 2, 2017 Exchange Agreement 2 689,796 4,200 $ 6.09 $ 4,200,000 July 7, 2017 114,286 — $ 17.50 $ 2,000,000 August 4, 2017 38,906 — $ 24.50 $ 1,015,848 August 28, 2017 Restructuring Agreement 3 117,171 — $ 10.50 $ 1,200,000 November 6, 2017 Warrant Exchange 4 — — $ — $ 279,016 November 15, 2017 Exchange Agreements 5 97,448,072 — $ 0.08 $ 8,130,564 Retirement per December 28, 2017 Exchange Agreements 6 — — $ — $ 553,234 December 28, 2017 Exchange Agreements 6 123,708,735 — $ 0.02 $ 2,474,174 Total 222,575,755 $ 35,000,000 1 2 3 4 5 6

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Stockholders Equity Note [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity Reverse Stock Split On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred and fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-three hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split. On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split. In addition, shareholders of the Company also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000. The previously discussed reverse stock split had no impact on the increase in authorized shares. Preferred Stock Issuances Series A Preferred Stock On June 29, 2017, the Company’s Board authorized the establishment of a new series of preferred stock designated as Series A Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series A Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series A Preferred Stock”). On July 2, 2017, the Company entered into an exchange agreement (the “Exchange”) with one of its investors which had purchased the Notes of $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock (the “Series A Preferred Shares”). The Exchange was made in reliance upon the exemption from registration provided by Rule 3(a)(9) of the Securities Act of 1933, as amended. The Series A Preferred Shares were entitled to the whole number of votes equal to $4.2 million divided by $1,288.00 (the closing bid price on June 13, 2016, the date of issuance of the Notes) or 3,261 votes. The Series A Preferred Stock had no dividend, liquidation or other preferential rights to the Company’s common stock, and each share of Series A Preferred Stock was redeemed for the amount of $0.001, paid in cash pursuant to the Restructuring Agreement signed on August 28, 2017 and discussed in further detail in Note 9. Series B Preferred Stock On June 29, 2017, the Company’s Board authorized the establishment of a new series of preferred stock designated as Series B Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series B Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series B Preferred Stock”). On July 11, 2017, the Company entered into a securities purchase agreement with existing holders of Notes pursuant to which the investors purchased $2,360,000 of Series B Preferred Stock for a cash purchase price of $2,000,000 in a private placement. The Series B Preferred Stock was entitled to the whole number of votes equal to $2.0 million divided by $65.35 (the closing bid price on July 5, 2017, the date of the original securities purchase agreement for the Series B Preferred Stock), or 30,607 votes. The Series B Preferred Stock had no liquidation or other preferential rights (but had the redemption rights described below) to the Company’s common stock and could have been converted into shares of common stock at a price equal to $53.55 per share upon the earlier of the date of closing to the extent that the holder thereof reallocated shares of our common stock reserved for issuance under its Notes to conversion of the Series B Preferred Shares and otherwise upon receipt of shareholder approval of the Reverse Stock Split. The Series B Preferred Stock allowed for optional redemption by the Company at any time after issuance or the holders at any time after the tenth business day prior to the maturity date. In the instance of a Financing, the Company was required to redeem the Series B Preferred Stock. The $360,000 difference between the redemption amount and the cash purchase price of the Series B Preferred Stock, as well as all issuance costs related to the Series B Preferred Stock, have been recorded as a deemed dividend. The Series B Preferred Stock was redeemed for $2,360,000 pursuant to the Restructuring Agreement signed on August 28, 2017 with one investor and upon a redemption notice from the second investor as discussed in further detail in Note 9. Series C Preferred Stock On September 12, 2017, the Company’s Board authorized the establishment of a new series of preferred stock designated as Series C Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock which was filed with the State of Delaware on September 20, 2017. On September 21, 2017, the Company entered into a securities purchase agreement with the two investors which had purchased Notes of $0.5 million aggregate purchase price for 590 shares of Series C Preferred Stock. The purchase of the Series C Preferred Stock is being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended. The Series C Preferred Stock shall be entitled to 1,484,061 votes and may only vote on approval of a reverse split of our outstanding common stock. The Series C Preferred Stock has no dividend, liquidation or other preferential rights to the Company’s common stock, and each share of Series C Preferred Stock shall be redeemable for the amount of $1,000.00, payable in cash per share at our written election, and must be redeemed no later than December 21, 2017. Because the Series C Preferred Stock was mandatorily redeemable, it has been recorded as a liability with the difference between the purchases price and the fair value being recognized over the term of the instrument. Additionally, all expenses related to the issuance of the Series C Preferred Stock are recognized as a debt discount and have been amortized over the term of the instrument. Per the terms of the October 22, 2017 Amendment to the Restructuring Agreement, the Series C Preferred Stock was redeemed for $590,000 on November 6, 2017. Stock and Warrant Issuances In October 2013, the Company completed the sale of 234 shares of its common stock and the issuance of warrants to purchase approximately 106 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2017, the 2013 Warrants were exercisable at $39,424 per share with 106 warrants outstanding. The 2013 Warrants have a five-year term. In February 2015, the Company completed the sale of 440 shares of its common stock and the issuance of warrants to purchase 197 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2017, the February 2015 Warrants were exercisable at $49.00 per share with approximately 92 warrants outstanding. The February 2015 Warrants have a five-year term. There were approximately 114 February 2015 Warrants exercised during the year ended December 31, 2016 for proceeds of approximately $0.1 million. In July 2015, the Company completed the sale of approximately 1,670 Units consisting of 1,670 shares of its common stock, Series A Warrants to purchase up to approximately 1,253 common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 1,670 million common shares (“Series B Warrants”) and 1,253 Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the year ended December 31, 2016, approximately 399 Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 1,271 Series B Warrants expired on January 29, 2016 and the related liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 399 Series A Warrants were issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2017, the July 2015 Series A Warrants were exercisable at $49.00 with approximately 541 million warrants outstanding. The Series A Warrants have a five-year term. There were approximately 300 July 2015 Series A Warrant exercised during the year ended December 31, 2017 for proceeds of approximately $15,000. There were approximately 700 July 2015 Series A Warrants exercised during the year ended December 31, 2016 for proceeds of $0.4 million. In June 2016, the Company entered into a SPA pursuant to which the Company issued $35.0 million in principal face amount of the Notes and related Series C Warrants to purchase 19,368 additional shares of the Company’s common stock. The Company allocated an estimated fair value of $27.8 million to the Series C Warrants. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case are to be paid to the respective investor, in exchange for cancellation of the Series C Warrants issued to each investor under the SPA. During 2017, 112.2 million common shares and rights to receive 108.9 million common shares were issued to satisfy the Notes. In October 2016, the Company completed the sale of 1,215 shares of its common stock and the issuance of warrants to purchase 425 common shares (the “October 2016 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $1.2 million, with net cash proceeds after related expenses from this transaction of $1.1 million. Of those proceeds, the Company allocated an estimated fair value of $0.3 million to the October 2016 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At December 31, 2017, the October 2016 Warrants were exercisable at $49.00 per share with 225 warrants outstanding. The October 2016 Warrants have a five-year term. There were 200 October 2016 Series C Warrants exercised during the year ended December 31, 2016 for proceeds of $0.1 million. Pursuant to the October 10, 2017 Amendment to the Restructuring Agreement, 127,551 warrants were issued to each of the two investors from the June 2016 SPA on November 6, 2017 following the effectuation of the reverse stock split discussed earlier. The warrants contain a cashless exercise provision that allows the holders to exercise each warrant for three shares of common stock. The warrants have a 4.5 year term and an exercise price of $122.50. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. As of December 31, 2017, 122,551 warrants have been exercised resulting in the issuance of 367,653 common shares. 5,000 warrants remain outstanding at December 31, 2017. In November 2017, the Company issued 7.0 million warrants pursuant to an Exchange Agreement entered into with each of the two investors from the June 2016 SPA. The Company allocated an estimated fair value of $14.4 million to the November 2017 Warrants. The exercise price is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At December 31, 2017, the November 2017 Warrants were exercisable at $2.45 per share with 7.0 million warrants outstanding. The November 2017 Warrants have a five-year term from the date of exercisability. In October 2015, the Company filed a registration statement on Form S-3 with the SEC, which was declared effective on October 20, 2015 and allows the Company to offer and sell, from time to time in one or more offerings, up to $71.8 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deems prudent or necessary to raise capital at a later date. The Company is not currently eligible to use its Form S-3. Stock Incentive Plans The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 34 and 573 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 304 shares, from 269 to 573 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of December 31, 2017, there were 83 A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options and Restricted Stock granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee. Options granted under the Plans expire over varying terms, but not more than ten years from the date of grant. Stock option activity for 2017, 2016 and 2015 is as follows: Stock Option Activity under the Plans Stock Options Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2014 51 $6,944 - $1,372,672 $ 132,328.00 8.83 Granted 94 6,664 6,664.00 Forfeited (9 ) 6,664-949,760 168,056.00 Outstanding at December 31, 2015 136 $6,664-$1,372,672 $ 42,840.00 8.95 Granted — — — Forfeited (48 ) 6,664-190,848 8,382.50 Outstanding at December 31, 2016 88 $6,644-$1,326,080 $ 12,815.73 7.90 Granted 42 $ 84.00 $ 84.00 Forfeited (3 ) $ 6,664.00 $ 6,664.00 Outstanding at December 31, 2017 127 $84.00-$381,696.00 $ 8,750.55 7.79 Exercisable at December 31, 2017 75 $6,664.00 - $381,696.00 $ 13,882.03 7.10 For the years ended December 31, 2017, 2016 and 2015 the Company recognized compensation expense related to stock option grants of approximately $0.1 million, $0.2 million and $0.3 million, respectively. The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants made in 2017 and 2015. There were no option grants during 2016. Year ended December 31, Year ended December 31, 2017 2015 Weighted average risk-free interest rates 2.15 % 1.82 % Weighted average expected volatility 170.42 % 97.70 % Dividend yield — — Weighted average expected option term (in years) 7.29 5.15 Weighted average grant date fair value $ 82.34 $ 4,964.73 No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term is based on actual historical results. A summary of the Company’s non-vested options to purchase shares as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below: Non-Vested Options Number of Options Weighted Average Exercise Price Non-vested at December 31, 2015 101 $ 7,892.50 Granted — — Vested (45 ) 9,397.50 Forfeited (114 ) 6,730.50 Non-vested at December 31, 2016 25 $ 6,686.40 Granted 42 84 Vested (13 ) 6,707.08 Forfeited (2 ) 6,664.00 Non-vested at December 31, 2017 52 $ 1,349.38 Additional compensation expense of approximately $6,800, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 0.42 years. The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2017 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $0.9 as of December 31, 2017, which would have been received by the option holders had those option holders exercised their options as of that date. A summary of the Company’s restricted stock activity as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below: Restricted Stock Activity Number of Shares Weighted Average Grant Date Fair Value Non-vested at December 31, 2015 103 $ 6,664.00 Granted 13 1,512.00 Vested (55 ) 5,404.00 Forfeited (15 ) 6,664.00 Non-vested at December 31, 2016 46 $ 6,664.00 Granted 261 84.00 Vested (24 ) 6,664.00 Forfeited — — Non-vested at December 31, 2017 283 $ 595.52 For the three years ended December 31, 2017, 2016 and 2015 the Company recognized compensation expense related to restricted stock grants of approximately $0.1 million, $0.3 and $0.3 million, respectively. Additional compensation expense of approximately $23,600 relating to the unvested portion of restricted stock granted is expected to be recognized over a remaining average period of 0.4 years. Warrants The Company issued warrants as part of its offerings in 2013, 2015, and 2016 as well as part of its issuance of convertible notes in 2016 and an exchange agreement in 2017. A summary of warrant activity is as follows: Warrants Exercise per Share Weighted Average Exercise Price Weighted Average Remaining Life (Years) Outstanding at January 1, 2014 152 $9,800-$39,424 $ 30,341.76 2.78 Issued 3,120 4,480.00 Exercised (39 ) 4,592.00 Expired (8 ) 4,592.00 Outstanding at December 31, 2015 3,224 $4,144-$39,424 $ 5,607.33 2.16 Issued 20,091 1,680.00 Exercised (1,428 ) 963.00 Expired (1,271 ) 1,988.00 Outstanding at December 31, 2016 20,616 $563.50-$39,424 $ 1,820.00 5.59 Issued 7,127,551 4.60 Exercised (122,848 ) 8.44 Expired (19,367 ) 1,690.50 Outstanding at December 31, 2017 7,005,952 $2.45-$39,424 $ 3.14 4.88

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	(11) Fair Value Measurements Derivative Financial Instruments As disclosed in Note 10 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K, the Company allocated part of the proceeds of public offerings in 2013, 2015 and 2016 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes and allocated an estimated fair value of $14.4 million to warrants issued pursuant to an exchange agreement signed in November 2017 discussed in further detail in Note 9 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K. The valuations of the October 2013, February 2015, July 2015 Series A, October 2016 and November 2017 Warrants (collectively, the “Warrants”) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy. For the year ended December 31, 2017, the Company recorded pre-tax derivative instrument income of $15.1 million. The resulting derivative instrument liabilities totaled $0.6 million at December 31, 2017. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2017 was determined by using option pricing models assuming the following: November 2017 Warrants October 2016 Warrants July 2015 Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 217.39% 130.88% 161.87% 169.95% 266.92% Risk free interest rates 1.98% 2.06% 1.94% 1.90% 1.68% Expected life (in years) 4.88 3.76 2.56 2.13 0.82 The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016, aggregated by the level in the fair value hierarchy within which those measurements fall. Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and Liabilities Measured at Fair Value on a Recurring Basis Level 1 Level 2 Level 3 Balance at December 31, (in thousands) 2017 2016 2017 2016 2017 2016 2017 2016 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 560 $ 18,751 $ 560 $ 18,751 Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at January 1, 2015 $ 225 Total change in the liability included in earnings (564 ) Fair value of warrants issued 4,247 Fair value of warrants exercised (123 ) Balance at December 31, 2015 3,785 Total change in the liability included in earnings (12,780 ) Fair value of warrants issued 28,472 Fair value of warrants exercised (726 ) Balance at December 31, 2016 $ 18,751 Total change in the liability included in earnings (15,103 ) Extinguishment of convertible note warrant (17,489 ) Fair value of warrants issued 16,953 Fair value of warrants exercised (2,552 ) Balance at December 31, 2017 $ 560

Commitments

Commitments	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments	(12) Commitments Operating Leases In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space at 810 Seventh Avenue, New York, NY with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010. In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Initial Lease and the Lease Amendment provide for annual rent of $996,000 in 2015, $1.0 million in 2016, and $1.1 million in 2017-2020. As discussed in Note 8, the Company has sub-leased this office space. In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath’s European headquarters. The Lease is for a term of ten years, commencing August, 2011. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The remaining annual lease amount is (USD conversion is based on the December 31, 2017 conversion rate):– €183,179 ($143,726). Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited’s payment obligations and performance of the Lease are guaranteed by Delcath. The Company has sub-leased a portion of this facility. In March 2016, the Company entered into a sub-lease agreement to lease approximately 6,877 square feet of office space at 1633 Broadway, New York, NY. The term began in April 2016 and is effective through March 2019. The agreement provides for total annual base rent of $522,652. In October 2016, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on November 1, 2016 and was effective for a two year period. The agreement provides for total annual base rent of $48,223 and will expire October 2018. Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2017 are as follows: (in thousands) Future Payment 2018 872 2019 501 2020 456 2021 281 2022 — 2023 — $ 2,110 For the years ended December 31, 2017, 2016, and 2015 rent expense totaled approximately $0.6 million, $0.5 million and $0.4 million, respectively. Letters of Credit Under the terms of the lease agreement for office space at 810 Seventh Avenue, New York, NY, the Company is required to maintain a letter of credit in the amount of $881,297 which will expire in February 2019 if not renewed by the Company. Under the terms of a sub-lease agreement for office space at 1633 Broadway, New York, NY, the Company is required to maintain a letter of credit in the amount of $130,663 which will expire with the sublease in March 2019.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes There is no income tax provision for the years ended December 31, 2017, 2016 and 2015. Income (loss) before income taxes consists of: Year Ended December 31, (in thousands) 2017 2016 2015 Domestic $ (41,313 ) $ (13,930 ) $ (11,276 ) Foreign (3,804 ) (4,040 ) (3,428 ) Income (loss) before taxes $ (45,117 ) $ (17,970 ) $ (14,704 ) The provision for income taxes differs from the amount computed by applying the statutory rate as follows: Year Ended December 31, (in thousands) 2017 2016 2015 Income taxes using U.S federal statutory rate $ (15,340 ) $ (6,110 ) $ (4,999 ) Tax Cuts and Jobs Act 143 — — Nondeductible interest 6,912 — — Loss on extinguishment of debt 10,174 Loss of tax benefit of federal net operating loss carryforwards 5,067 68,795 — Loss of tax benefit of state net operating loss carryforwards 1,373 13,891 — Loss of tax benefit of federal tax credit carryforwards 324 4,023 — Amortization of gain on IP migration 767 767 767 State income taxes, net of federal benefit (1,339 ) (2,576 ) 380 Foreign rate differential 1,196 1,141 920 Valuation allowance (1,423 ) (75,407 ) 2,649 Derivative charge (8,403 ) (4,345 ) (192 ) Stock option exercises and cancellations 841 53 674 Research and development costs (295 ) (250 ) (199 ) Other 3 18 — $ — $ — $ — Significant components of the Company’s deferred tax assets are as follows: Year Ended December 31, (in thousands) 2017 2016 2015 Deferred tax assets: Employee compensation accruals $ 292 $ 1,386 $ 1,279 Accrued liabilities 353 343 633 Research tax credits 17 22 3,796 Other 34 55 66 Net operating losses 5,289 6,194 77,906 Total deferred tax assets 5,985 8,000 83,680 Deferred tax liabilities: Beneficial conversion feature — 906 — Other 13 — — Total deferred tax liabilities 13 906 — Valuation allowance 5,972 7,094 83,680 Net deferred tax assets $ — $ — $ — As of December 31, 2017, 2016 and 2015, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $211.3 million, $209.3 million and $184.5 million, respectively. A significant portion of the federal amount, $210.5 million, is subject to an annual limitation of approximately $27,500 as a result of a changes in the Company’s ownership in May 2003, November 2016 and multiple dates throughout 2017, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitations caused by the May 2003, November 2016 and multiple 2017 ownership changes, approximately $209.5 million of the total net operating loss carryforwards is expected to expire unutilized and will be unavailable to offset future federal taxable income. Approximately $1.0 million of net operating loss carryforwards remains available to offset future federal taxable income which will expire between 2018 and 2037. In addition, the Company’s state net operating losses are also subject to annual limitations that generally follow the federal Section 382 provisions (with the exception of Connecticut), adjusted for each state’s respective income apportionment percentages. As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for state and city income tax purposes between approximately $27.3 million and $150.3 million and between approximately $27.3 million and $153.0, respectively, which expire through 2037. As a result of the 382 limitations, approximately $149.0 million and $133.3 million of New York State and New York City net operating losses are expected to expire unutilized and will be unavailable to offset future taxable income. Approximately $0.8 million and $0.8 million of net operating loss carryforwards, respectively, will be available to offset future state and city taxable income. As of December 31, 2017, 2016 and 2015, the Company had a net operating loss carryforward for foreign income tax purposes of $25.0 million, $21.1 million and $22.1 million, respectively, which have indefinite carryforward periods. As of December 31, 2017, 2016 and 2015, the Company had federal research and development tax credit carryforwards of approximately $4.3 million, $4.0 million and $3.8 million, respectively, which expire through 2037. As a result of the section 382 limitation, the entire tax credit carryforward is expected to expire unutilized. Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company’s valuation allowance decreased by approximately $1.1 million and $76.6 million in 2017 and 2016, respectively. The primary reason for the significant decrease in the valuation allowance during 2016 is due to the reduction of recognizable deferred tax assets related net operating loss and credit carryforwards resulting from the Sec. 382 ownership change. The change in valuation allowance is as follows: (in thousands) December 31, 2017 December 31, 2016 Beginning balance $ 7,094 $ 83,680 Charged to costs and expenses (1,423 ) (75,407 ) Charged to additional paid-in capital — (1,854 ) Charged to retained earnings — 1,010 Charged to other comprehensive income 301 (335 ) Ending balance $ 5,972 $ 7,094 On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”). The Act, which is also commonly referred to as “U.S. tax reform”, significantly changes U.S. corporate income tax laws by, among other provisions, reducing the maximum U.S. corporate income tax rate from 35% to 21% starting in 2018. At December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Act; however, as described below, the Company has made a reasonable estimate of the effects on its existing deferred tax balances and the one-time transition tax. The Company is continuing to assess the impact from the Act and will record adjustments in 2018 if necessary. During the year ended December 31, 2017, the Company reduced deferred tax assets by a provisional amount of $143,500, offset by a corresponding reduction to its valuation allowance, as a result of the re-measurement of deferred tax assets and liabilities from its 34% effective rate under existing law to the new lower statutory rate of 21%. However, the Company is still analyzing certain aspects of the Act and refining its calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The Act also requires a mandatory one-time inclusion of the deferred foreign income of controlled foreign corporations. The one-time transition tax is based on Delcath’s total post-1986 earnings and profits (E&P) for which the Company has previously deferred from U.S. income taxes. The Company’s reasonable estimate resulted in no provisional amount for the one-time transition tax liability, as the Company’s international subsidiaries are expected to have a cumulative deficit in E&P. Delcath has not yet completed its calculation of the total post-1986 foreign E&P (including deficits) for these foreign subsidiaries. As the Company’s international subsidiaries have a cumulative deficit in earnings and profits, the Company does not anticipate being affected by the mandatory inclusion provisions of the Act. On December, 22, 2017, SAB 118 was issued due to the complexities involved in accounting for the recently enacted Act. SAB 118 requires the Company to include in its financial statements a reasonable estimate of the impact of the Act on earnings to the extent such estimate has been determined. Accordingly, the U.S. provision for income tax for 2017 is based on the reasonable estimate guidance provided by SAB 118. The Company is continuing to assess the impact from the Act and will record adjustments in 2018 if necessary. The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10 and therefore has not included a tabular rollfoward of unrecognized tax benefits. As there are no uncertain tax positions recognized, interest and penalties have not been accrued. The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. During the third quarter of 2015, the Internal Revenue Service commenced an examination of the Company’s federal income tax return for the year ended December 31, 2013. The examination was completed in the third quarter of 2017 and no changes were made to the reported amounts. Accordingly, there was no effect on the financial statements as a result of the examination. The Company has not been audited by any state tax authorities in connection with income taxes. The Company has not been audited by international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company is no longer subject to federal and state examination for tax years ending prior to December 31, 2014; tax years ending December 31, 2014 through December 31, 2017 remain open to examination. The Republic of Ireland is the Company’s only significant foreign jurisdiction. The Company is no longer subject to Ireland tax examination for tax years ending prior to December 31, 2013 (as Ireland has not initiated an audit of 2012 as of December 31, 2017); tax years ending December 31, 2013 through December 31, 2017 remain open to examination. However, the Company’s tax years December 31, 1998 through December 31, 2017 generally remain open to adjustment for all federal, state and foreign tax matters until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization, and the applicable statutes of limitation have expired in the utilization year. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	(14) Quarterly Financial Data (Unaudited) Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2017 and 2016. 2017 Quarters Ended (in thousands, except per share amounts) March 31 June 30 September 30 December 31 Revenue $ 743 $ 584 $ 684 $ 704 Costs and expenses 4,736 5,050 5,139 5,254 Operating loss (4,212 ) (4,601 ) (4,627 ) (4,725 ) Net loss (11,332 ) (1,943 ) (12,596 ) (19,246 ) Basic loss per share (87.50 ) (3.50 ) (9.36 ) (0.75 ) 2016 Quarters Ended (in thousands, except per share amounts) March 31 June 30 September 30 December 31 Revenue $ 370 $ 511 $ 435 $ 676 Costs and expenses 3,721 4,232 5,047 4,882 Operating loss (3,462 ) (3,871 ) (4,724 ) (4,383 ) Net loss (1,813 ) (6,667 ) (1,004 ) (8,486 ) Basic loss per share (437.50 ) (1,543.50 ) (230.99 ) (1,292.02 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	(15) Subsequent Events As of January 25, 2018, all of the Rights issued under the December 28, 2017 Exchange Agreements discussed in more detail in Note 9 to the Company’s consolidated financial statements contained in this Annual Report on Form 10-K have been exercised resulting in the issuance of 108.9 million shares. On February 9, 2018, the Company closed a registered offering of 212,000,000 shares of common stock, 38,000,000 pre-funded warrants to purchase 38,000,000 shares of common stock and Series D warrants to purchase an aggregate of 500,000,000 shares of common stock for total gross proceeds of approximately $5.0 million. The offering was priced at $0.02 per unit with each unit comprised of one share of common stock (or one pre-funded warrant) and one common stock purchase warrant to purchase two shares, provided that, with respect to the units with pre-funded warrants $0.019 per unit shall be paid at closing and $0.001 shall be paid upon exercise of each of the pre-funded warrants. The warrants carry a five-year term from the date of initial exercisability (which is later of one year from the date of issuance and date of amendment to articles of incorporation to increase number of authorized shares of common stock) with an exercise price of $0.02 per share. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-220898) previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on February 7, 2018. After consummation of this offering, the Company has 434,981,824 shares of its common stock issued and outstanding. On February 26, 2018, the Company filed a Definitive Proxy Statement on Schedule 14A seeking shareholder approval to increase its authorized shares of common stock from 500,000,000 to 1,000,000,000 in order to have sufficient authorized shares for full exercise of its recently issued Series D Warrants and for a reverse split of its common stock at a ratio of at least 1:100 but no more than 1:500,

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Liquidity	Liquidity The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has accumulated deficit of $324.8 million at December 31, 2017. As shown in the accompanying financial statements during the year ended December 31, 2017, the Company incurred net losses of $45.1 million and used $15.4 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. Adequate additional financing may not be available to us on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce or eliminate our research and development programs or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. If Delcath is not able to continue as a going concern, it is likely that holders of its common stock will lose all of their investment. The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations through May 2018. Additional working capital will be required to continue operations.
Use of Estimates	Use of Estimates The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.
Cash Equivalents and Concentrations of Credit Risk	Cash Equivalents and Concentrations of Credit Risk The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.
Restricted Cash	Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying consolidated balance sheets.
Accounts Receivable	Accounts Receivable Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified.
Inventories	Inventories Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory. Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2017 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable.
Derivative Instrument Liability	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with Accounting Standards Codification (ASC) 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.
Fair Value Measurements	Fair Value Measurements The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. • Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. • Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
Revenue Recognition	Revenue Recognition Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied.
Deferred Revenue	Deferred Revenue Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied.
Selling, General and Administrative	Selling, General and Administrative Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred.
Research and Development	Research and Development Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.
Stock Based Compensation	Stock Based Compensation The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expenses its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant. The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.
Income Taxes	Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. See Note 13 for additional information.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 are as follows: (in thousands, except share data) 2017 2016 2015 Net loss $ (45,117 ) $ (17,971 ) $ (14,704 ) Preferred stock dividends (527 ) — — Net loss, adjusted (45,644 ) (17,971 ) (14,704 ) Net loss per share – basic and diluted (6.50 ) (3,707 ) (5,096 ) Weighted average shares outstanding – basic and diluted 7,019,316 4,847 2,887 In the third quarter of 2017, the Company issued Series B Preferred Shares. A portion of the redemption price of the Series B Preferred Shares was accounted for as a deemed dividend and is discussed further in Note 10. For the years ended December 31, 2017, 2016 and 2015, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive. Shares excluded from the computation of diluted EPS: 2017 2016 2015 Stock options 127 118 135 Unvested restricted shares 283 55 103 Warrants 7,005,952 20,618 3,225 Total 7,006,362 20,791 3,463 All share numbers presented in this footnote reflect a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017
Segment Information	Segment Information The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.
Foreign Currency and Currency Translation	Foreign Currency and Currency Translation Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statements of operations. The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.
Recently Adopted Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company will adopt this standard on January 1, 2018 using the modified retrospective method. The Company has completed an analysis of its existing product sales and distribution agreement and assessed the differences in accounting for each under ASU 2014-09 compared with current revenue accounting standards. Based on that review, the Company does not expect the implementation of ASU 2014-09 to have a material quantitative impact on its consolidated financial statements as the timing of revenue recognition for product sales is not expected to change considerably. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company has adopted this guidance. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company will adopt this standard on January 1, 2018 and does not anticipate that this guidance will materially impact its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Calculation of net loss and number of shares used to compute basic and diluted earnings per share	The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 are as follows: (in thousands, except share data) 2017 2016 2015 Net loss $ (45,117 ) $ (17,971 ) $ (14,704 ) Preferred stock dividends (527 ) — — Net loss, adjusted (45,644 ) (17,971 ) (14,704 ) Net loss per share – basic and diluted (6.50 ) (3,707 ) (5,096 ) Weighted average shares outstanding – basic and diluted 7,019,316 4,847 2,887
Shares excluded from the computation of diluted EPS	Shares excluded from the computation of diluted EPS: 2017 2016 2015 Stock options 127 118 135 Unvested restricted shares 283 55 103 Warrants 7,005,952 20,618 3,225 Total 7,006,362 20,791 3,463

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consist of: (in thousands) December 31, 2017 December 31, 2016 Raw materials $ 298 $ 346 Work-in-process 721 214 Finished goods 229 100 Total Inventory $ 1,248 $ 660

Prepaid Expenses and Other Cu27

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets include the following: (in thousands) December 31, 2017 December 31, 2016 Insurance premiums $ 421 $ 501 Financing costs 70 — Security deposit 50 50 Other 1 159 147 Total prepaid expenses and other current assets $ 700 $ 698 1

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Components of property, plant and equipment	Property, plant, and equipment consists of: (in thousands) December 31, 2017 December 31, 2016 Buildings and land $ 579 $ 556 Enterprise hardware and software 1,744 1,532 Leaseholds 1,705 1,504 Equipment 971 940 Furniture 175 354 Property, plant and equipment, gross 5,174 4,886 Accumulated depreciation (3,876 ) (3,803 ) Property, plant and equipment, net $ 1,298 $ 1,083

Current Accrued Expenses (Table

Current Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Payables And Accruals [Abstract]
Schedule of current accrued expenses	Current accrued expenses include the following: (in thousands) December 31, 2017 December 31, 2016 Clinical trial expenses $ 869 $ 1,365 Compensation, excluding taxes 1,124 933 Professional fees 221 286 Short-term portion of lease restructuring 209 216 Other 1 985 607 Total accrued expenses $ 3,408 $ 3,407 1

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Schedule of restructuring and related costs	The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2017: (in thousands) Lease Liability Reserve balance at December 31, 2016 $ 820 Charges — Payments/Utilizations (216 ) Reserve balance at December 31, 2017 $ 604

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Summary of Common Stock and Preferred Stock Shares Issued under Notes and New Notes	The Company has issued shares of Common Stock and Preferred Stock as payments of principal (including certain early repayments at the option of the holders) and effected a retirement under the Notes and New Notes as follows: Number of Shares of Common Stock Number of Shares of Preferred Stock Applicable Conversion Price Reduction in Principal January 12, 2017 11,753 — $ 126.00 $ 1,478,318 January 26 - February 1, 2017 1 4,857 — $ 112.00 $ 544,000 February 10, 2017 43,882 — $ 70.00 $ 3,045,817 February 23 - March 2, 2017 1 2,571 — $ 49.00 $ 125,999 March 13, 2017 117,297 — $ 38.50 $ 4,417,829 April 10, 2017 169,061 — $ 21.00 $ 3,621,286 May 9, 2017 109,367 — $ 17.50 $ 1,913,915 June 7 / July 2, 2017 Exchange Agreement 2 689,796 4,200 $ 6.09 $ 4,200,000 July 7, 2017 114,286 — $ 17.50 $ 2,000,000 August 4, 2017 38,906 — $ 24.50 $ 1,015,848 August 28, 2017 Restructuring Agreement 3 117,171 — $ 10.50 $ 1,200,000 November 6, 2017 Warrant Exchange 4 — — $ — $ 279,016 November 15, 2017 Exchange Agreements 5 97,448,072 — $ 0.08 $ 8,130,564 Retirement per December 28, 2017 Exchange Agreements 6 — — $ — $ 553,234 December 28, 2017 Exchange Agreements 6 123,708,735 — $ 0.02 $ 2,474,174 Total 222,575,755 $ 35,000,000 1 2 3 4 5 6

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders Equity Note [Abstract]
Stock option activity	Stock option activity for 2017, 2016 and 2015 is as follows: Stock Option Activity under the Plans Stock Options Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2014 51 $6,944 - $1,372,672 $ 132,328.00 8.83 Granted 94 6,664 6,664.00 Forfeited (9 ) 6,664-949,760 168,056.00 Outstanding at December 31, 2015 136 $6,664-$1,372,672 $ 42,840.00 8.95 Granted — — — Forfeited (48 ) 6,664-190,848 8,382.50 Outstanding at December 31, 2016 88 $6,644-$1,326,080 $ 12,815.73 7.90 Granted 42 $ 84.00 $ 84.00 Forfeited (3 ) $ 6,664.00 $ 6,664.00 Outstanding at December 31, 2017 127 $84.00-$381,696.00 $ 8,750.55 7.79 Exercisable at December 31, 2017 75 $6,664.00 - $381,696.00 $ 13,882.03 7.10
Assumptions used to determine estimated fair value of stock options granted	The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants made in 2017 and 2015. There were no option grants during 2016. Year ended December 31, Year ended December 31, 2017 2015 Weighted average risk-free interest rates 2.15 % 1.82 % Weighted average expected volatility 170.42 % 97.70 % Dividend yield — — Weighted average expected option term (in years) 7.29 5.15 Weighted average grant date fair value $ 82.34 $ 4,964.73
Summary of non-vested options	A summary of the Company’s non-vested options to purchase shares as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below: Non-Vested Options Number of Options Weighted Average Exercise Price Non-vested at December 31, 2015 101 $ 7,892.50 Granted — — Vested (45 ) 9,397.50 Forfeited (114 ) 6,730.50 Non-vested at December 31, 2016 25 $ 6,686.40 Granted 42 84 Vested (13 ) 6,707.08 Forfeited (2 ) 6,664.00 Non-vested at December 31, 2017 52 $ 1,349.38
Summary of restricted stock activity	A summary of the Company’s restricted stock activity as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below: Restricted Stock Activity Number of Shares Weighted Average Grant Date Fair Value Non-vested at December 31, 2015 103 $ 6,664.00 Granted 13 1,512.00 Vested (55 ) 5,404.00 Forfeited (15 ) 6,664.00 Non-vested at December 31, 2016 46 $ 6,664.00 Granted 261 84.00 Vested (24 ) 6,664.00 Forfeited — — Non-vested at December 31, 2017 283 $ 595.52
Summary of warrant activity	A summary of warrant activity is as follows: Warrants Exercise per Share Weighted Average Exercise Price Weighted Average Remaining Life (Years) Outstanding at January 1, 2014 152 $9,800-$39,424 $ 30,341.76 2.78 Issued 3,120 4,480.00 Exercised (39 ) 4,592.00 Expired (8 ) 4,592.00 Outstanding at December 31, 2015 3,224 $4,144-$39,424 $ 5,607.33 2.16 Issued 20,091 1,680.00 Exercised (1,428 ) 963.00 Expired (1,271 ) 1,988.00 Outstanding at December 31, 2016 20,616 $563.50-$39,424 $ 1,820.00 5.59 Issued 7,127,551 4.60 Exercised (122,848 ) 8.44 Expired (19,367 ) 1,690.50 Outstanding at December 31, 2017 7,005,952 $2.45-$39,424 $ 3.14 4.88

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of fair value of the warrants	The fair value of the Warrants at December 31, 2017 was determined by using option pricing models assuming the following: November 2017 Warrants October 2016 Warrants July 2015 Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 217.39% 130.88% 161.87% 169.95% 266.92% Risk free interest rates 1.98% 2.06% 1.94% 1.90% 1.68% Expected life (in years) 4.88 3.76 2.56 2.13 0.82
Assets and liabilities measured at fair value on a recurring basis	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016, aggregated by the level in the fair value hierarchy within which those measurements fall. Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and Liabilities Measured at Fair Value on a Recurring Basis Level 1 Level 2 Level 3 Balance at December 31, (in thousands) 2017 2016 2017 2016 2017 2016 2017 2016 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 560 $ 18,751 $ 560 $ 18,751
Fair value measurements using significant unobservable inputs	Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at January 1, 2015 $ 225 Total change in the liability included in earnings (564 ) Fair value of warrants issued 4,247 Fair value of warrants exercised (123 ) Balance at December 31, 2015 3,785 Total change in the liability included in earnings (12,780 ) Fair value of warrants issued 28,472 Fair value of warrants exercised (726 ) Balance at December 31, 2016 $ 18,751 Total change in the liability included in earnings (15,103 ) Extinguishment of convertible note warrant (17,489 ) Fair value of warrants issued 16,953 Fair value of warrants exercised (2,552 ) Balance at December 31, 2017 $ 560

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments, net of receipts due under terms of subleases under all operating leases	Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2017 are as follows: (in thousands) Future Payment 2018 872 2019 501 2020 456 2021 281 2022 — 2023 — $ 2,110

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Income Taxes	Income (loss) before income taxes consists of: Year Ended December 31, (in thousands) 2017 2016 2015 Domestic $ (41,313 ) $ (13,930 ) $ (11,276 ) Foreign (3,804 ) (4,040 ) (3,428 ) Income (loss) before taxes $ (45,117 ) $ (17,970 ) $ (14,704 )
Income tax reconciliation	The provision for income taxes differs from the amount computed by applying the statutory rate as follows: Year Ended December 31, (in thousands) 2017 2016 2015 Income taxes using U.S federal statutory rate $ (15,340 ) $ (6,110 ) $ (4,999 ) Tax Cuts and Jobs Act 143 — — Nondeductible interest 6,912 — — Loss on extinguishment of debt 10,174 Loss of tax benefit of federal net operating loss carryforwards 5,067 68,795 — Loss of tax benefit of state net operating loss carryforwards 1,373 13,891 — Loss of tax benefit of federal tax credit carryforwards 324 4,023 — Amortization of gain on IP migration 767 767 767 State income taxes, net of federal benefit (1,339 ) (2,576 ) 380 Foreign rate differential 1,196 1,141 920 Valuation allowance (1,423 ) (75,407 ) 2,649 Derivative charge (8,403 ) (4,345 ) (192 ) Stock option exercises and cancellations 841 53 674 Research and development costs (295 ) (250 ) (199 ) Other 3 18 — $ — $ — $ —
Significant components of deferred tax assets	Significant components of the Company’s deferred tax assets are as follows: Year Ended December 31, (in thousands) 2017 2016 2015 Deferred tax assets: Employee compensation accruals $ 292 $ 1,386 $ 1,279 Accrued liabilities 353 343 633 Research tax credits 17 22 3,796 Other 34 55 66 Net operating losses 5,289 6,194 77,906 Total deferred tax assets 5,985 8,000 83,680 Deferred tax liabilities: Beneficial conversion feature — 906 — Other 13 — — Total deferred tax liabilities 13 906 — Valuation allowance 5,972 7,094 83,680 Net deferred tax assets $ — $ — $ —
Summary of Change in Valuation Allowance	The change in valuation allowance is as follows: (in thousands) December 31, 2017 December 31, 2016 Beginning balance $ 7,094 $ 83,680 Charged to costs and expenses (1,423 ) (75,407 ) Charged to additional paid-in capital — (1,854 ) Charged to retained earnings — 1,010 Charged to other comprehensive income 301 (335 ) Ending balance $ 5,972 $ 7,094

Quarterly Financial Data (Una36

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected quarterly financial data	Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2017 and 2016. 2017 Quarters Ended (in thousands, except per share amounts) March 31 June 30 September 30 December 31 Revenue $ 743 $ 584 $ 684 $ 704 Costs and expenses 4,736 5,050 5,139 5,254 Operating loss (4,212 ) (4,601 ) (4,627 ) (4,725 ) Net loss (11,332 ) (1,943 ) (12,596 ) (19,246 ) Basic loss per share (87.50 ) (3.50 ) (9.36 ) (0.75 ) 2016 Quarters Ended (in thousands, except per share amounts) March 31 June 30 September 30 December 31 Revenue $ 370 $ 511 $ 435 $ 676 Costs and expenses 3,721 4,232 5,047 4,882 Operating loss (3,462 ) (3,871 ) (4,724 ) (4,383 ) Net loss (1,813 ) (6,667 ) (1,004 ) (8,486 ) Basic loss per share (437.50 ) (1,543.50 ) (230.99 ) (1,292.02 )

Description of Business - Addit

Description of Business - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Net loss	$ 19,246	$ 12,596	$ 1,943	$ 11,332	$ 8,486	$ 1,004	$ 6,667	$ 1,813	$ 45,117	$ 17,971	$ 14,704
Net cash used in operating activities									15,398	14,213	$ 16,420
Accumulated deficit	$ 324,832				$ 279,188				$ 324,832	$ 279,188

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Additional Information (Details)	Nov. 06, 2017	Jul. 21, 2016	Jul. 19, 2016	Dec. 31, 2017Segment
Summary Of Significant Accounting Policies [Line Items]
Maximum period of investments with original maturities from date of acquisition to be cash equivalents				3 months
Reverse stock split ratio	0.0029	0.0625
Number of business segments				1
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives				3 years
Reverse stock split ratio			0.1
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives				7 years
Reverse stock split ratio			0.05

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended								12 Months Ended
		Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Calculation of net loss and the number of shares used to compute basic and diluted earnings per share [Abstract]
Net loss		$ (19,246)	$ (12,596)	$ (1,943)	$ (11,332)	$ (8,486)	$ (1,004)	$ (6,667)	$ (1,813)	$ (45,117)	$ (17,971)	$ (14,704)
Preferred stock dividends										(527)
Net loss, adjusted										$ (45,644)	$ (17,971)	$ (14,704)
Net loss per share – basic and diluted	[1]									$ (6.50)	$ (3,707)	$ (5,096)
Weighted average shares outstanding – basic and diluted	[1]									7,019,316	4,847	2,887
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017.

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Summary of Shares Excluded from the Computation of Diluted EPS (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,006,362	20,791	3,463
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	127	118	135
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	283	55	103
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,005,952	20,618	3,225

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 298	$ 346
Work-in-process	721	214
Finished goods	229	100
Total Inventory	$ 1,248	$ 660

Prepaid Expenses and Other Cu42

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 421	$ 501
Financing costs	70
Security deposit	50	50
Other	159	147
Total prepaid expenses and other current assets	$ 700	$ 698

Prepaid Expenses and Other Cu43

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

Property, Plant, and Equipmen44

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 5,174	$ 4,886
Accumulated depreciation	(3,876)	(3,803)
Property, plant and equipment, net	1,298	1,083
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	579	556
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,744	1,532
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,705	1,504
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	971	940
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 175	$ 354

Property, Plant, and Equipmen45

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 310	$ 305	$ 617

Current Accrued Expenses - Sche

Current Accrued Expenses - Schedule of Current Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Clinical trial expenses	$ 869	$ 1,365
Compensation, excluding taxes	1,124	933
Professional fees	221	286
Short-term portion of lease restructuring	209	216
Other	985	607
Total accrued expenses	$ 3,408	$ 3,407

Current Accrued Expenses - Sc47

Current Accrued Expenses - Schedule of Current Accrued Expenses (Parenthetical) (Details)	Dec. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

Restructuring Expenses - Additi

Restructuring Expenses - Additional Information (Details) $ in Thousands	Aug. 18, 2014USD ($)	May 22, 2014USD ($)	Dec. 31, 2017USD ($)Lease	Dec. 31, 2016USD ($)
Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Number of sub leases | Lease			2
Restructuring reserve balance			$ 604	$ 820
Sub-lease 1 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900
Sub Lease 2 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700
Other non-current liabilities [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			400
Accrued Expenses [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			$ 200

Restructuring Expenses - Schedu

Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) - Lease Liability [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 820
Payments/Utilizations	(216)
Restructuring reserve balance	$ 604

Convertible Notes Payable - Add

Convertible Notes Payable - Additional Information (Details)	Dec. 28, 2017USD ($)dshares	Nov. 15, 2017USD ($)Investor$ / sharesshares	Nov. 06, 2017	Oct. 11, 2017USD ($)d$ / shares	Oct. 10, 2017USD ($)Investorshares	Sep. 21, 2017USD ($)$ / shares	Sep. 15, 2017USD ($)$ / sharesshares	Aug. 28, 2017USD ($)$ / sharesshares	Aug. 04, 2017USD ($)$ / shares	Jul. 07, 2017USD ($)$ / shares	Jul. 02, 2017USD ($)$ / shares	May 09, 2017USD ($)$ / shares	Apr. 10, 2017USD ($)$ / shares	Apr. 02, 2017USD ($)	Mar. 13, 2017USD ($)$ / shares	Mar. 02, 2017USD ($)$ / shares	Feb. 10, 2017USD ($)$ / shares	Feb. 01, 2017USD ($)$ / shares	Jan. 12, 2017USD ($)$ / shares	Jul. 21, 2016	Jul. 19, 2016	Jun. 13, 2016	Jun. 06, 2016USD ($)Installment$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 28, 2017USD ($)dshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / shares	Dec. 31, 2014$ / shares
Debt Instrument [Line Items]
Gain (loss) on warrant extinguishment		$ (21,000,000)																									$ 9,613,000		$ 0	$ 0
Warrant liability fair value adjustment																											(15,103,000)		(12,780,000)	(564,000)
Debt instrument, conversion price | $ / shares									$ 24.50	$ 17.50		$ 17.50	$ 21		$ 38.50	$ 49	$ 70	$ 112	$ 126
Reverse stock split ratio			0.0029																	0.0625
Conversion of convertible notes									$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286		$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318								40,121,000	$ 35,000,000	649,000	$ 0
Debt instrument extended prepayment date		Mar. 31, 2018
Fair value of beneficial conversion feature of convertible note																											$ 4,908,000		$ 4,435,000
Aggregate shares of common stock issued to investors | shares																								11,805		114,055,137	114,055,137		11,805
Common stock, shares outstanding (in shares) | shares																								11,750		114,054,851	114,054,851		11,750
Minimum [Member]
Debt Instrument [Line Items]
Reverse stock split ratio																					0.1
Exercise price of warrants | $ / shares																								$ 563.50		$ 2.45	$ 2.45		$ 563.50	$ 4,144	$ 9,800
Maximum [Member]
Debt Instrument [Line Items]
Reverse stock split ratio																					0.05
Exercise price of warrants | $ / shares																								$ 39,424		$ 39,424	$ 39,424		$ 39,424	$ 39,424	$ 39,424
Additional Paid-in Capital [Member]
Debt Instrument [Line Items]
Fair value of beneficial conversion feature of convertible note																											$ 4,908,000		$ 4,435,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share | $ / shares											$ 0.001
Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share | $ / shares						$ 1,000
Payment for redemption of preferred stock																											$ 590,000		0	$ 0
Conversion of convertible notes						$ 500,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Gain (loss) on warrant extinguishment					$ (2,300,000)
Initial release of restricted cash								$ 1,650,000
Conversion of convertible notes								$ 1,200,000
Restructuring Agreement [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share | $ / shares								$ 4.20
Restructuring Agreement [Member] | Series B Preferred Stock [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock								$ 2,006,000
Restructuring Agreement [Member] | Investor [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of preferred stock | shares								4,200
Restructuring Agreement [Member] | Investor [Member] | Series B Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of preferred stock | shares								2,006
Restructuring Agreement [Member] | Investor [Member] | Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes								$ 11,444,637
Additional Restructuring [Member]
Debt Instrument [Line Items]
Reverse stock split ratio							20
Gain (loss) on warrant extinguishment							$ 1,900,000
Loss on debt settlement							$ 1,200,000
Additional Restructuring [Member] | New Warrants [Member]
Debt Instrument [Line Items]
Shares issuable upon warrants exercised | shares							2.125
Warrants expiry period							42 months
Exercise price of warrants | $ / shares							$ 122.50
Amendment to Restructuring Agreement [Member]
Debt Instrument [Line Items]
Shares issuable upon warrants exercised | shares																										367,653	367,653
Exercise price of warrants | $ / shares																										$ 122.50	$ 122.50
Loss on debt settlement				$ 300,000
Warrants issued to purchase Common Stock | shares					127,551																					127,551
Extinguishment of remaining outstanding obligations under notes				300,000
Loss on debt settlements by issuing warrants				$ 2,300,000
Term period for warrants																										4 years 6 months
Amendment to Restructuring Agreement [Member] | Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Redemption of shares outstanding for cash payment					$ 590,000
Exchange Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes		$ 10,562,425
Shares issuable upon warrants exercised | shares	108,900,000																											108,900,000
Exercise price of warrants | $ / shares		$ 2.45
Number of Notes investors entered into agreement	2	2																										2
Warrants issued to purchase Common Stock | shares		7,000,000
Extinguishment of remaining outstanding obligations under notes	$ 3,000,000
Number of Notes investors entered into agreement	2	2																										2
Debt instrument date of agreement	Dec. 28, 2017	Nov. 15, 2017
Term period for warrants		5 years
Interest expense		$ 300,000
Release of restrictions on restricted cash held in control accounts	$ 2,046,898
Shares of common stock issued to investors | shares	14,800,000
Aggregate shares of common stock issued to investors | shares	123,708,735																									14,800,000	14,800,000	123,708,735
Cash payment to investors from restricted cash held	$ 829,831
Common stock, shares outstanding (in shares) | shares																										14,800,000	14,800,000
Loss on debt settlements by issuing shares and debt	$ 3,700,000
Exchange Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Percentage of beneficial ownership by investor of issued and outstanding stock	4.90%
Exchange Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of beneficial ownership by investor of issued and outstanding stock	9.90%
Securities Purchase Agreement [Member] | Warrant Repurchase Agreements [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants														$ 7,900,000
Gain (loss) on warrant extinguishment														9,600,000
Warrant liability fair value adjustment														$ 17,500,000
Series C Warrants [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants																											$ 7,876,000		0	0
Release of restrictions on restricted cash held in control accounts																											7,876,000		$ 0	$ 0
Series C Warrants [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Additional issuance of common stock purchase price per share. | $ / shares																							$ 0.01
Series C Warrants [Member] | Securities Purchase Agreement [Member] | Warrant Repurchase Agreements [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants																									$ 7,900,000
Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes																										$ 0	$ 0
Senior Secured Convertible Notes [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion of convertible notes											$ 4,200,000
Senior Secured Convertible Notes [Member] | Amendment to Restructuring Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price | $ / shares				$ 0.05
Number of Notes investors entered into agreement | Investor					2
Conversion of convertible notes					$ 279,015
Conversion price of debt instrument to purchase price of common stock percentage.				200.00%
Debt instrument, maturity description																											the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018
Debt instrument maturity date				Dec. 30, 2018
Debt instrument, deferred description																											until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period
Debt instrument, conversion treshold days | d				75
Debt instrument, redemption description																											the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes
Redemption of outstanding debt instrument for cash				$ 7,300,000
Number of Notes investors entered into agreement | Investor					2
Senior Secured Convertible Notes [Member] | Amendment to Restructuring Agreement [Member] | Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Cash held in the restricted accounts				$ 600,000
Senior Secured Convertible Notes [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes		11,157,970
Debt instrument, principal face amount		10,600,000
Gain (loss) on warrant extinguishment		(19,000,000)
Fair value of new notes including conversion feature		15,200,000
Debt instrument, fair value		10,300,000
Senior Secured Convertible Notes [Member] | Exchange Agreement [Member] | Additional Paid-in Capital [Member]
Debt Instrument [Line Items]
Fair value of beneficial conversion feature of convertible note	$ 4,900,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																							$ 35,000,000
Debt discount on senior notes																							2,800,000			35,000,000	$ 35,000,000
Proceeds from issuance of notes available for general corporate purposes																							$ 3,000,000	$ 3,000,000
Amortization payments number of equal installments | Installment																							14
Period after original date of issuance of notes for which amortization payment begins																						7 months
Debt instrument, original issuance date																						Jun. 13, 2016
Debt instrument, conversion price | $ / shares																							$ 1,536.50
Debt discount amortization																											35,000,000
Beneficial conversion feature																											4,400,000
Debt issuance costs																										$ 2,200,000	$ 2,200,000
Senior Secured Convertible Notes [Member] | Series C Warrants [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																									$ 35,000,000
Senior Secured Convertible Notes [Member] | Series C Warrants [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants																							$ 32,200,000
Debt discount on senior notes																							$ 27,800,000
Shares issuable upon warrants exercised | shares																							20,000
Senior Secured Convertible Notes [Member] | Warrants [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Derivative liability, at calculated fair value		$ 14,400,000
Restricted Notes [Member] | Restructuring Agreement [Member] | Investor [Member] | Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes								10,092,857
Unrestricted Notes [Member] | Restructuring Agreement [Member] | Investor [Member] | Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes								1,351,780
Cancellation Note [Member] | Restructuring Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal of notes cancelled								$ 1,200,000
Redemption Notes [Member] | Additional Restructuring [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount							$ 4,000,000
Debt instrument, redemption price							6,436,852.80
Exchange Notes [Member] | Additional Restructuring [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount							$ 2,436,852.80
Exchange Notes [Member] | Additional Restructuring [Member] | New Warrants [Member]
Debt Instrument [Line Items]
Common stock shares purchased | shares							114,286
New Notes [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price | $ / shares		$ 1.50
Extinguishment of remaining outstanding obligations under notes	$ 3,027,408
Debt instrument conversion price of lowest vwap for common stock percentage		82.00%
Debt instrument conversion price of lowest vwap for common stock in event of default percentage		75.00%

Convertible Notes Payable - Sum

Convertible Notes Payable - Summary of Common Stock and Preferred Stock Shares Issued under Notes and New Notes (Details) - USD ($)	Dec. 28, 2017	Nov. 15, 2017	Nov. 06, 2017	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	Jun. 07, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Dec. 31, 2017	Dec. 28, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Applicable Conversion Price					$ 24.50	$ 17.50			$ 17.50	$ 21	$ 38.50	$ 49	$ 70	$ 112	$ 126
Reduction in Principal					$ 1,015,848	$ 2,000,000			$ 1,913,915	$ 3,621,286	$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318	$ 40,121,000	$ 35,000,000	$ 649,000	$ 0
Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares	123,700,000
Applicable Conversion Price	$ 0.02	$ 0.08						$ 6.09									$ 0.02
Reduction in Principal	$ 2,474,174	$ 8,130,564					$ 4,200,000	$ 4,200,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price				$ 10.50
Reduction in Principal				$ 1,200,000
Warrant Exchange [Member]
Debt Instrument [Line Items]
Reduction in Principal			$ 279,016
Retirement Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	$ 553,234
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of Shares					38,906	114,286			109,367	169,061	117,297	2,571	43,882	4,857	11,753		222,575,755
Common Stock Issued [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares	123,708,735	97,448,072					689,796	689,796
Common Stock Issued [Member] | Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				117,171
Preferred Stock Issued [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares								4,200

Convertible Notes Payable - S52

Convertible Notes Payable - Summary of Common Stock and Preferred Stock Shares Issued under Notes and New Notes (Parenthetical) (Details) - USD ($)	Dec. 28, 2017	Nov. 15, 2017	Oct. 10, 2017	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	Jun. 07, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Dec. 31, 2017	Dec. 28, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Reduction in Principal					$ 1,015,848	$ 2,000,000			$ 1,913,915	$ 3,621,286	$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318	$ 40,121,000	$ 35,000,000	$ 649,000	$ 0
Gain (loss) on warrant extinguishment		$ (21,000,000)														$ 9,613,000		$ 0	$ 0
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal				$ 1,200,000
Loss on debt settlement				$ 1,900,000
Gain (loss) on warrant extinguishment			$ (2,300,000)
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued					38,906	114,286			109,367	169,061	117,297	2,571	43,882	4,857	11,753		222,575,755
Common Stock Issued [Member] | Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued				117,171
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued							4,200
Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	$ 2,474,174	$ 8,130,564					$ 4,200,000	$ 4,200,000
Number of shares issued	123,700,000
Loss on debt settlement							$ 1,000,000
Gain (loss) on warrant extinguishment	$ (3,700,000)
Exchange Agreement [Member] | Retirement Per Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	$ 600,000
Exchange Agreement [Member] | Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued	123,708,735	97,448,072					689,796	689,796
Exchange Agreement [Member] | Provision to Exchange [Member]
Debt Instrument [Line Items]
Reduction in Principal		$ 600,000
Number of shares issued		973,764
Exchange Agreement [Member] | Updated Conversion Price Formula [Member]
Debt Instrument [Line Items]
Reduction in Principal		$ 7,500,000
Number of shares issued		96,500,000
Exchange Agreement [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued							4,200

Stockholders' Equity - Reverse

Stockholders' Equity - Reverse Stock Split - Additional Information (Details)	Nov. 06, 2017$ / sharesshares	Jul. 21, 2016$ / sharesshares	Jul. 19, 2016shares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares	Jul. 18, 2016shares	Dec. 31, 2015$ / shares
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029	0.0625
Number of fractional shares were issued in connected with the reverse stock split		0
Common stock, par value (in dollars per share) | $ / shares		$ 0.01		$ 0.01	$ 0.01		$ 0.01
Common stock, shares authorized (in shares)			500,000,000	500,000,000	500,000,000	170,000,000
Minimum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.1
Maximum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.05
OTCQB [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connected with the reverse stock split	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details)	Sep. 21, 2017USD ($)InvestorVote$ / sharesshares	Aug. 28, 2017USD ($)shares	Aug. 04, 2017USD ($)	Jul. 11, 2017USD ($)Vote$ / shares	Jul. 07, 2017USD ($)	Jul. 02, 2017USD ($)Vote$ / sharesshares	May 09, 2017USD ($)	Apr. 10, 2017USD ($)	Mar. 13, 2017USD ($)	Mar. 02, 2017USD ($)	Feb. 10, 2017USD ($)	Feb. 01, 2017USD ($)	Jan. 12, 2017USD ($)	Oct. 31, 2016USD ($)	Feb. 28, 2015USD ($)	Oct. 31, 2013USD ($)	Dec. 31, 2017USD ($)$ / shares	Dec. 31, 2017USD ($)$ / shares	Dec. 28, 2017USD ($)	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2015USD ($)	Nov. 06, 2017USD ($)	Sep. 12, 2017$ / shares	Jun. 29, 2017$ / shares
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares																	$ 0.01	$ 0.01		$ 0.01
Conversion of convertible notes			$ 1,015,848		$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318					$ 40,121,000	$ 35,000,000	$ 649,000	$ 0
Sale of stock in private placement																				1,011,000	8,479,000
Gross proceeds from the sale of shares														$ 1,200,000	$ 2,600,000	$ 7,500,000
Deemed dividend amount																		$ 527,000		$ 0	$ 0
Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes		$ 1,200,000
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares																								$ 0.01
Number of Shares | shares						4,200
Closing bid price | $ / shares						$ 1,288
Number of votes | Vote						3,261
Preferred stock redemption price per share | $ / shares						$ 0.001
Series A Preferred Stock [Member] | Senior Secured Convertible Notes [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes						$ 4,200,000
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares																								$ 0.01
Closing bid price | $ / shares				$ 65.35
Number of votes | Vote				30,607
Sale of stock in private placement				$ 2,360,000
Cash purchase price in private placement				2,000,000
Gross proceeds from the sale of shares				$ 2,000,000
Conversion price per share | $ / shares				$ 53.55
Deemed dividend amount																	$ 360,000
Series B Preferred Stock [Member] | Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Redeemed share | shares		2,360,000
Series C Preferred Shares [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares																							$ 0.01
Conversion of convertible notes	$ 500,000
Number of Shares | shares	590
Number of votes | Vote	1,484,061
Preferred stock redemption price per share | $ / shares	$ 1,000
Number of investors | Investor	2
Redemption of preferred stock																						$ 590,000

Stockholders' Equity - Stock an

Stockholders' Equity - Stock and Warrant Issuances - Additional Information (Details)	Oct. 10, 2017shares	Apr. 02, 2017USD ($)	Nov. 30, 2017USD ($)Investorshares	Oct. 31, 2016USD ($)shares	Jun. 30, 2016USD ($)shares	Jul. 31, 2015USD ($)shares	Feb. 28, 2015USD ($)shares	Oct. 31, 2013USD ($)shares	Dec. 31, 2017Investor$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Jun. 06, 2016USD ($)shares	Oct. 20, 2015USD ($)	Dec. 31, 2014$ / sharesshares
Stockholders Equity Note [Line Items]
Sale of common stock, net of expenses (in shares)				1,215		1,670	440	234
Proceeds from issuance of private placement | $				$ 1,200,000			$ 2,600,000	$ 7,500,000
Net proceeds from issuance of private placement | $				$ 1,100,000			$ 2,500,000	$ 6,900,000
Number of warrants outstanding (in shares)									7,005,952	7,005,952	20,616	3,224			152
Sale of units to underwriter						1,670
Proceeds of common stock issued, net of related expenses | $						$ 6,000,000
Maximum [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 39,424	$ 39,424	$ 39,424	$ 39,424			$ 39,424
Maximum offering and selling of stock and securities that entity make to raise capital | $														$ 71,800,000
Minimum [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 2.45	2.45	$ 563.50	$ 4,144			$ 9,800
Amendment to Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock	127,551								127,551
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 122.50	$ 122.50
Number of warrants outstanding (in shares)									5,000	5,000
Term period for warrants									4 years 6 months
Warrants exercised (in shares)									122,551
Number of investors | Investor									2
Warrants exercise price description										The warrants contain a cashless exercise provision that allows the holders to exercise each warrant for three shares of common stock.
Shares issuable upon warrants exercised									367,653	367,653
Securities Purchase Agreement [Member] | Warrant Repurchase Agreements [Member]
Stockholders Equity Note [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants | $		$ 7,900,000
Common Shares [Member]
Stockholders Equity Note [Line Items]
Sale of common stock, net of expenses (in shares)											1,223	2,109
Common shares and rights issued										113,643,624	5,158
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Debt instrument, principal face amount | $													$ 35,000,000
Senior Secured Convertible Notes [Member] | Rights [Member]
Stockholders Equity Note [Line Items]
Common shares and rights issued										108,900,000
Senior Secured Convertible Notes [Member] | Common Shares [Member]
Stockholders Equity Note [Line Items]
Common shares and rights issued										112,200,000
Series A Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 49	$ 49
Number of warrants outstanding (in shares)									541,000,000	541,000,000
Warrants exercised (in shares)										300	700
Net proceeds from exercise of warrants | $										$ 15,000	$ 400,000
Number of warrants converted						1,253					399
Gross proceeds from underwriting offering | $						$ 7,000,000
Warrants expiry period										5 years
Series B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants exercised (in shares)											399
Net proceeds from exercise of warrants | $											$ 800,000
Number of warrants converted						1,670,000,000
Remaining outstanding warrants expired											1,271
Warrants expiration date										Jan. 29, 2016
Series A and B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued | $						$ 3,400,000
2013 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock								106
Value of warrants issued | $								$ 1,900,000
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 39,424	$ 39,424
Number of warrants outstanding (in shares)									106	106
Term period for warrants										5 years
February 2015 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock							197
Value of warrants issued | $							$ 800,000
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 49	$ 49
Number of warrants outstanding (in shares)									92	92
Term period for warrants										5 years
Warrants exercised (in shares)											114
Net proceeds from exercise of warrants | $											$ 100,000
Series C Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued | $					$ 27,800,000
Aggregate amount to be paid in exchange for cancellation of warrants | $										$ 7,876,000	$ 0	$ 0
Series C Warrants [Member] | Securities Purchase Agreement [Member] | Warrant Repurchase Agreements [Member]
Stockholders Equity Note [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants | $					$ 7,900,000
Series C Warrants [Member] | Senior Secured Convertible Notes [Member]
Stockholders Equity Note [Line Items]
Number of warrants converted					19,368
Debt instrument, principal face amount | $					$ 35,000,000
Series C Warrants [Member] | Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Shares issuable upon warrants exercised													20,000
October 2016 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock				425
Value of warrants issued | $				$ 300,000
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 49	$ 49
Number of warrants outstanding (in shares)									225	225
Term period for warrants										5 years
Warrants exercised (in shares)											200
Net proceeds from exercise of warrants | $											$ 100,000
November 2017 Warrants [Member] | Exchange Agreement [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock			7,000,000
Value of warrants issued | $			$ 14,400,000
Warrants exercisable per share price (in dollars per share) | $ / shares									$ 2.45	$ 2.45
Number of warrants outstanding (in shares)									7,000,000	7,000,000
Term period for warrants										5 years
Number of investors | Investor			2

Stockholders' Equity - Stock In

Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 50,000	$ 161,000	$ 349,000
Stock options granted		42		94
Additional compensation expense relating to stock options		$ 6,800
Restricted stock compensation expense		79,000	266,000	$ 308,000
Additional compensation expense relating to restricted stock		23,600
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 100,000	$ 200,000	300,000
Stock options granted			0
Remaining average recognition period for unrecognized compensation expense		5 months 1 day
Aggregate intrinsic value of options outstanding and exercisable		$ 0
Closing stock price (in dollars per share)		$ 0.9
Stock Options [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, term		10 years
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining average recognition period for unrecognized compensation expense		4 months 24 days
Restricted stock compensation expense		$ 100,000	$ 300,000	$ 300,000
2004 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)		34
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	269	573
Increased number of shares (in shares)	304
Shares available for grant		83

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Options, Number of Options [Roll Forward]
Outstanding, beginning of period (in shares)	88	136	51
Granted (in shares)	42		94
Forfeited (in shares)	(3)	(48)	(9)
Outstanding, end of period (in shares)	127	88	136	51
Exercisable (in shares)	75
Stock Options, Exercise Price per Share [Roll Forward]
Granted (in dollars per share)	$ 84		$ 6,664
Forfeited (in dollars per share)	6,664
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	12,815.73	$ 42,840	132,328
Granted (in dollars per share)	84		6,664
Forfeited (in dollars per share)	6,664	8,382.50	168,056
Outstanding, beginning of period (in dollars per share)	8,750.55	$ 12,815.73	$ 42,840	$ 132,328
Exercisable (in dollars per share)	$ 13,882.03
Stock Options, Weighted Average Remaining Life Years [Abstract]
Outstanding	7 years 9 months 14 days	7 years 10 months 24 days	8 years 11 months 12 days	8 years 9 months 29 days
Exercisable	7 years 1 month 6 days
Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 6,644	$ 6,664	$ 6,944
Forfeited (in dollars per share)		6,664	6,664
Outstanding, end of period (in dollars per share)	84	6,644	6,664	$ 6,944
Exercisable (in dollars per share)	6,664
Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	1,326,080	1,372,672	1,372,672
Forfeited (in dollars per share)		190,848	949,760
Outstanding, end of period (in dollars per share)	381,696	$ 1,326,080	$ 1,372,672	$ 1,372,672
Exercisable (in dollars per share)	$ 381,696

Stockholders' Equity - Assumpti

Stockholders' Equity - Assumptions Used to Determine Estimated Fair Value of Stock Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2015
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average grant date fair value (in dollars per share)	$ 84
Stock Options [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average risk-free interest rates (in hundredths)	2.15%	1.82%
Weighted average expected volatility (in hundredths)	170.42%	97.70%
Weighted average expected option term (in years)	7 years 3 months 14 days	5 years 1 month 24 days
Weighted average grant date fair value (in dollars per share)	$ 82.34	$ 4,964.73

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Non-vested Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Non-vested Options, Number of Options [Roll Forward]
Non-vested, beginning of period (in shares)	25	101
Granted (in shares)	42		94
Vested (in shares)	(13)	(45)
Forfeited (in shares)	(2)	(114)
Non-vested, end of period (in shares)	52	25	101
Non-vested Options, Weighted Average Exercise Price [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 6,686.40	$ 7,892.50
Granted (in dollars per share)	84
Vested (in dollars per share)	6,707.08	9,397.50
Forfeited (in dollars per share)	6,664	6,730.50
Non-vested, end of period (in dollars per share)	$ 1,349.38	$ 6,686.40	$ 7,892.50

Stockholders' Equity - Summar60

Stockholders' Equity - Summary of Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Restricted Stock, Number of Shares [Roll Forward]
Outstanding, beginning of period (in shares)	46	103
Granted (in shares)	261	13
Vested (in shares)	(24)	(55)
Forfeited (in shares)		(15)
Outstanding, end of period (in shares)	283	46
Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 6,664	$ 6,664
Granted (in dollars per share)	84	1,512
Vested (in dollars per share)	6,664	5,404
Forfeited (in dollars per share)		6,664
Non-vested, end of period (in dollars per share)	$ 595.52	$ 6,664

Stockholders' Equity - Summar61

Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	20,616	3,224	152
Issued (in shares)	7,127,551	20,091	3,120
Exercised (in shares)	(122,848)	(1,428)	(39)
Expired (in shares)	(19,367)	(1,271)	(8)
Outstanding, end of period (in shares)	7,005,952	20,616	3,224	152
Warrants, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 1,820	$ 5,607.33	$ 30,341.76
Issued (in dollars per share)	4.60	1,680	4,480
Exercised (in dollars per share)	8.44	963	4,592
Expired (in dollars per share)	1,690.50	1,988	4,592
Outstanding, end of period (in dollars per share)	$ 3.14	$ 1,820	$ 5,607.33	$ 30,341.76
Weighted average remaining life	4 years 10 months 17 days	5 years 7 months 2 days	2 years 1 month 28 days	2 years 9 months 11 days
Minimum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 2.45	$ 563.50	$ 4,144	$ 9,800
Maximum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 39,424	$ 39,424	$ 39,424	$ 39,424

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)Input	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Nov. 30, 2017USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of inputs used for valuation of warrants | Input	6
Derivative warrant liability [Abstract]
Change in fair value of the warrant liability, net	$ 15,103	$ 12,780	$ 564
Derivative warrant liabilities	$ 560	$ 18,751
November 2017 Warrants [Member] | Exchange Agreement [Member]
Derivative warrant liability [Abstract]
Value of warrants issued				$ 14,400

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Warrants (Details)	12 Months Ended
	Dec. 31, 2017
November 2017 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	217.39%
Risk free interest rates (in hundredths)	1.98%
Expected life (in years)	4 years 10 months 17 days
October 2016 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	130.88%
Risk free interest rates (in hundredths)	2.06%
Expected life (in years)	3 years 9 months 3 days
July 2015 Series A Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	161.87%
Risk free interest rates (in hundredths)	1.94%
Expected life (in years)	2 years 6 months 21 days
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	169.95%
Risk free interest rates (in hundredths)	1.90%
Expected life (in years)	2 years 1 month 17 days
October 2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	266.92%
Risk free interest rates (in hundredths)	1.68%
Expected life (in years)	9 months 25 days

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Derivative Instruments Liabilities [Member] - Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Liabilities [Abstract]
Total Liabilities	$ 560	$ 18,751
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 560	$ 18,751

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 18,751	$ 3,785	$ 225
Total change in the liability included in earnings	(15,103)	(12,780)	(564)
Extinguishment of convertible note warrant	(17,489)
Fair value of warrants issued	16,953	28,472	4,247
Fair value of warrants exercised	(2,552)	(726)	(123)
Ending balance	$ 560	$ 18,751	$ 3,785

Commitments - Additional Inform

Commitments - Additional Information (Details)	1 Months Ended		12 Months Ended
	Oct. 31, 2016USD ($)ft²	Mar. 31, 2016USD ($)ft²	Dec. 31, 2017USD ($)ft²	Dec. 31, 2017EUR (€)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Operating Leased Assets [Line Items]
Rent expense			$ 600,000		$ 500,000	$ 400,000
Office Space at 810 Seventh Avenue, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²			8,629
Expansion option, additional square footage of office space (in square feet) | ft²			8,629
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement			$ 881,297
Expiration date of letter of credit			Feb. 28, 2019	Feb. 28, 2019
Office Space in New York, NY, Lease Amendment [Member]
Operating Leased Assets [Line Items]
Additional square footage of office space leased under exercise of option right (in square feet) | ft²			8,629
Lease expiration date			Mar. 31, 2021	Mar. 31, 2021
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 4 [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 996,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 5 [Member]
Operating Leased Assets [Line Items]
Annual base rent			1,000,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Years Thereafter [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 1,100,000
Delcath's European Headquarters Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²			19,200
Annual base rent			$ 143,726	€ 183,179
Operating lease term			10 years	10 years
Office Space At 1633 Broadway, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²		6,877
Annual base rent		$ 522,652
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement					$ 130,663
Expiration date of letter of credit			Mar. 31, 2019	Mar. 31, 2019
Park Road Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²	6,000
Annual base rent	$ 48,223
Operating lease term			2 years	2 years
Lease expiration period			2018-10	2018-10

Commitments - Schedule Future M

Commitments - Schedule Future Minimum Lease Payments, Net of Receipts Due Under Terms of Subleases Under All Operating Leases (Details) $ in Thousands	Dec. 31, 2017USD ($)
Future minimum lease payments under all operating leases [Abstract]
2,018	$ 872
2,019	501
2,020	456
2,021	281
Total future minimum payments due	$ 2,110

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Income tax provision			$ 0	$ 0	$ 0
Percentage of valuation allowance against deferred tax assets			100.00%
Decrease in valuation allowance			$ 1,100,000	76,600,000
U.S. corporate income tax rate			34.00%
Tax Cuts and Jobs Act of 2017, accounting complete			false
Provisional income tax due to reduction in deferred tax assets			$ 143,500
Scenario, Plan [Member]
Operating Loss Carryforwards [Line Items]
U.S. corporate income tax rate		21.00%
New York State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income			149,000,000
New York City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income			$ 133,300,000
Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax period			Dec. 31, 1998
Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax period			Dec. 31, 2017
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 211,300,000	209,300,000	184,500,000
Operating loss carryforwards, amount subject to limitations			210,500,000
Operating loss carryforwards, annual limitation			27,500
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income			209,500,000
Federal [Member] | Expire Between 2018 and 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			1,000,000
Federal [Member] | Tax Year 2013 [Member]
Operating Loss Carryforwards [Line Items]
Examination of federal income tax return, date of examination	Dec. 31, 2013
Federal [Member] | Research and Development Tax Credit Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards			$ 4,300,000	4,000,000	3,800,000
Tax credit carryforwards, expiration dates			2,037
State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 800,000	800,000
Operating loss carryforwards, expiration dates			2,037
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 25,000,000	21,100,000	$ 22,100,000
Federal and State [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax period			Dec. 31, 2014
Federal and State [Member] | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax period			Dec. 31, 2017
Minimum [Member] | Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			2,018
Minimum [Member] | State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 27,300,000	27,300,000
Maximum [Member]
Operating Loss Carryforwards [Line Items]
U.S. corporate income tax rate			35.00%
Maximum [Member] | Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			2,037
Maximum [Member] | State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 150,300,000	$ 153,000,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments [Abstract]
Domestic	$ (41,313)	$ (13,930)	$ (11,276)
Foreign	(3,804)	(4,040)	(3,428)
Income (loss) before taxes	$ (45,117)	$ (17,970)	$ (14,704)

Income Taxes - Income tax recon

Income Taxes - Income tax reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Provision for income taxes [Abstract]
Income taxes using U.S federal statutory rate	$ (15,340,000)	$ (6,110,000)	$ (4,999,000)
Tax Cuts and Jobs Act	143,000
Nondeductible interest	6,912,000
Loss on extinguishment of debt	10,174,000
Loss of tax benefit of federal net operating loss carryforwards	5,067,000	68,795,000
Loss of tax benefit of state net operating loss carryforwards	1,373,000	13,891,000
Loss of tax benefit of federal tax credit carryforwards	324,000	4,023,000
Amortization of gain on IP migration	767,000	767,000	767,000
State income taxes, net of federal benefit	(1,339,000)	(2,576,000)	380,000
Foreign rate differential	1,196,000	1,141,000	920,000
Valuation allowance	(1,423,000)	(75,407,000)	2,649,000
Derivative charge	(8,403,000)	(4,345,000)	(192,000)
Stock option exercises and cancellations	841,000	53,000	674,000
Research and development costs	(295,000)	(250,000)	(199,000)
Other	3,000	18,000
Total	$ 0	$ 0	$ 0

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Employee compensation accruals	$ 292	$ 1,386	$ 1,279
Accrued liabilities	353	343	633
Research tax credits	17	22	3,796
Other	34	55	66
Net operating losses	5,289	6,194	77,906
Total deferred tax assets	5,985	8,000	83,680
Deferred tax liabilities:
Beneficial conversion feature		906
Other	13
Total deferred tax liabilities	13	906	0
Valuation allowance	5,972	7,094	83,680
Net deferred tax assets	$ 0	$ 0	$ 0

Income Taxes - Summary of Chang

Income Taxes - Summary of Change in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Beginning balance	$ 7,094	$ 83,680
Charged to costs and expenses	(1,423)	(75,407)	$ 2,649
Charged to additional paid-in capital		(1,854)
Charged to retained earnings		1,010
Charged to other comprehensive income	301	(335)
Ending balance	$ 5,972	$ 7,094	$ 83,680

Quarterly Financial Data (Una73

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 704	$ 684	$ 584	$ 743	$ 676	$ 435	$ 511	$ 370	$ 2,715	$ 1,992	$ 1,747
Costs and expenses	5,254	5,139	5,050	4,736	4,882	5,047	4,232	3,721	20,179	17,882	16,495
Operating loss	(4,725)	(4,627)	(4,601)	(4,212)	(4,383)	(4,724)	(3,871)	(3,462)	(18,165)	(16,440)	(15,210)
Net loss	$ (19,246)	$ (12,596)	$ (1,943)	$ (11,332)	$ (8,486)	$ (1,004)	$ (6,667)	$ (1,813)	$ (45,117)	$ (17,971)	$ (14,704)
Basic loss per share	$ (0.75)	$ (9.36)	$ (3.50)	$ (87.50)	$ (1,292.02)	$ (230.99)	$ (1,543.50)	$ (437.50)

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ / shares in Units, $ in Millions	Feb. 26, 2018shares	Feb. 09, 2018USD ($)$ / sharesshares	Nov. 06, 2017	Jul. 21, 2016	Jul. 19, 2016shares	Jan. 25, 2018shares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares	Jul. 18, 2016shares	Dec. 31, 2015$ / shares	Dec. 31, 2014$ / shares
Subsequent Event [Line Items]
Common stock, shares issued (in shares)							114,055,137	11,805
Common stock, shares outstanding (in shares)							114,054,851	11,750
Common stock, shares authorized (in shares)					500,000,000		500,000,000	500,000,000	170,000,000
Reverse stock split ratio			0.0029	0.0625
Minimum [Member]
Subsequent Event [Line Items]
Warrants exercisable per share price (in dollars per share) | $ / shares							$ 2.45	$ 563.50		$ 4,144	$ 9,800
Reverse stock split ratio					0.1
Maximum [Member]
Subsequent Event [Line Items]
Warrants exercisable per share price (in dollars per share) | $ / shares							$ 39,424	$ 39,424		$ 39,424	$ 39,424
Reverse stock split ratio					0.05
Subsequent Event [Member] | Minimum [Member] | Board of Directors [Member]
Subsequent Event [Line Items]
Common stock, shares authorized (in shares)	500,000,000
Reverse stock split ratio	0.01
Subsequent Event [Member] | Maximum [Member] | Board of Directors [Member]
Subsequent Event [Line Items]
Common stock, shares authorized (in shares)	1,000,000,000
Reverse stock split ratio	0.002
Subsequent Event [Member] | Registered Offering [Member]
Subsequent Event [Line Items]
Number of registered common stock offering		212,000,000
Number of pre-funded warrants		38,000,000
Number of pre-funded warrants to purchase shares of common stock		38,000,000
Gross proceeds from sale of warrants | $		$ 5
Offering price | $ / shares		$ 0.02
Number of common stock purchase warrant		1
Number of shares to purchase upon common stock purchase warrant		2
Purchase of common stock warrants, pre-funded warrants shall be paid at offering, per unit | $ / shares		$ 0.019
Purchase of common stock warrants, pre-funded warrants shall be paid upon exercise, per unit | $ / shares		$ 0.001
Warrants expiration period		5 years
Warrants exercisable per share price (in dollars per share) | $ / shares		$ 0.02
Common stock, shares issued (in shares)		434,981,824
Common stock, shares outstanding (in shares)		434,981,824
Subsequent Event [Member] | Series D Warrants [Member] | Registered Offering [Member]
Subsequent Event [Line Items]
Number of warrants to purchase aggregate shares of common stock		500,000,000
Subsequent Event [Member] | Common Stock Issued [Member] | Registered Offering [Member]
Subsequent Event [Line Items]
Offering share issued		1
Subsequent Event [Member] | Warrants [Member] | Registered Offering [Member]
Subsequent Event [Line Items]
Offering share issued		1
Exchange Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issuable upon warrants exercised						108,900,000